Johnson&Johnson	Cell Therapy Product Procedures Manual			
JOHNSON	Document No.:	TV-eFRM-13010	Version:	3.0

# Cell Therapy Investigational Product Procedures Manual (CTPPM)

Cilta-Cel (Ciltacabtagene Autoleucel) Program

Version 5.0 **Final** Date: 12-APR-2024

Region: NA - North America

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOIIISOII & OOIIIISOII	Document No.:	TV-eFRM-13010	Version:	3	.0

# **Program CTPPM Approval**

I approve the content of this document.

Name	Role	Signature	Date (DD-MON-YYYY)
Sadaf Naz Khan	CTL	See Program CTPPM V5.0 12-April-2024 Approval Page	12-April-2024
Kristen Wightman	GTL	See Program CTPPM V5.0 12-April-2024 Approval Page	12-April-2024
Pedro Rodriguez	CSOM	See Program CTPPM V5.0 12-April-2024 Approval Page	12-April-2024
Tom Reijns	CSI	See Program CTPPM V5.0 12-April-2024 Approval Page	12-April-2024

Johnson&Johnson	Cell Therapy Product Procedures Manual				
oomison & oomison	Document No.:	TV-eFRM-13010	Version:	3.0	o

# **Regional Approval**

I approve the content of this document.

Name	Role	Signature	Date (DD-MON-YYYY)
Angela Trinh	Global Trial Leader (GTL)	Angela Trinh Reach Paris	igned by Angela Trinh b=JNJ, ou=Subscribers, cn=Angela 2342.19200300.100.1.1=402583 am approving this document 4.05.07 22:39:43 -07'00' robat Reader version: 2020.013.20064
Agne Taraseviciute- Morris	Study Responsible Physician or Scientist (SRP/SRS)	Taraseviciute-	signed by Agne Taraseviciute-Morris gne Taraseviciute-Morris, o=JnJ, email=atarasev@its.jnj.com, c=US am approving this document 4.05.07 11:15:26 -07'00' robat Reader version: .20687
Janice Brown	Clinical Trial Manager (CTM)	Janice  DN: cn=J Operatio c=GB Reason: I Date: 202	igned by Janice Brown anice Brown, o, ou=Global Clinical ns, email=jbrow196@its.jnj.com, am approving this document. 4,05,08 09:08:36 +01'00' crobat DC version: 2015.006.30505

Johnson & Johnson

Document No.:

Cell Therapy Product Procedures Manual

TV-eFRM-13010 Version: 3.0

# **Table of Contents**

Table of Contents	4	
Introduction		6
Records		8
Module 1: Pre-Collection	11	
1.1 Study Supplies		14
1.2 Pre-Collection Activities (All Subjects)		15
Module 2: Apheresis & Cell Management	17	
2.1 Apheresis Labeling		21
2.2 Apheresis Collection		24
2.3 Cell Management		25
Module 3: Cell Transfer	26	
Module 4: Cryopreservation Procedure		
4.1 Cryopreservation: Labeling		
4.2 Cryopreservation and LN₂ Storage		35
4.3 Cryopreservation Shipping: Communication Plan with Site, Courier and Sponsor		
4.4 Cryopreservation Shipping: Review of Packing Materials		37
4.5 Cryopreservation Shipping: Instructions for Receipt of Empty LN2 Shipper		39
4.6 Cryopreservation Shipping: Packing of cryopreserved apheresis material into the $LN_2$ Shipper		44
Module 5: Packaging and Shipment	52	
5.1 Communication Plan with Site, Courier & Sponsor		56
5.2 Review of Packing Materials		57
5.3 Packing of Apheresis Material into the CREDO CUBE Shipper for USA only		59
5.3 Packing of Apheresis Material into the CREDO CUBE Shipper for Canada only		63
5.4 Courier Pick Up of the Packed CREDO CUBE Shipper		67
Module 6: Receipt and Storage of the Investigational Product	68	
6.1 Communication Plan with Site, Courier & Sponsor		72
6.2 Review of Packing Materials		73
6.3 Receipt of the LN <sub>2</sub> Shipper Containing Investigational Product		75
6.4 Unpacking and Storage of Investigational Product		80
6.5 Prepare of Empty LN <sub>2</sub> Shipper for Shipment		87
6.6 Storage and Monitoring of IP		89
6.7 Problems and Special Situations		91
Module 7: Return and On-site Destruction of IP	94	
7.1 Communication Plan with Site, Courier, and Sponsor		97
7.2 Review of Packing Materials		98
7.3 Instructions for Receipt of Empty LN <sub>2</sub> Shipper		100
7.4 Packing of Investigational Product into LN <sub>2</sub> Shipper		105

	Johnson&Johnson		Cell Therapy Product Pro	ocedures Manual	
		Document No.:	TV-eFRM-13010	Version:	3.0
7.5 D	Discontinuing or Withdrav	ving a Subject from Inve	stigational Product		113
7.6 C	On-Site Destruction of Inv	estigational Product			114
Mod	ule 8: COI/COC Maps &	Forms			115
8.1 S	Summary of Chain of Cus	tody and Chain of Identi	ty Documents		118
8.2 C	Chain of Custody/Chain o	f Identity Forms			119
8.3 C	Chain of Custody/Chain o	f Identity Cryo Forms			120

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOTHISOTICOOTHISOTI	Document No.:	TV-eFRM-13010	Version:	3.0

## Introduction

#### **Cell Therapy Product Procedures Manual (CTPPM)**

The CTPPM provides end to end instructions to investigational site personnel on the sponsor's requirements and processes for enrollment, apheresis collection, storage, and shipment to and from the manufacturer.

Instructions provided in this document must be followed precisely. Any deviations from the instructions, whether intentional or accidental, must be documented and reported to the site manager (SM).

For trials outsourced to a Contract Research Organization (CRO), references to a site manager (SM) refer to the appropriate CRO title e.g., Clinical Research Associate (CRA).

#### Preparation, Dispensing, and Administration of IP

See the Investigational Product Preparation Instructions (IPPI) for sponsor instructions on preparing, dispensing, and administering the IP. The IPPI is located in the site IP Binder.

Follow the site's standard procedures for preparation of IP in alignment with the sponsor instructions. If the site does not have written procedures, contact the SM for guidance.

Two qualified staff members should be involved whenever the IP is prepared by the site; one to prepare the IP and the other to check or verify.

Guidance on the use of sponsor provided or site provided ancillary supplies will be provided in the IPPI.

### **General Principles in Conducting Clinical Studies**

The conduct of clinical studies and the associated activities outlined in this manual are subject to various local, national, and international regulations. Furthermore, each site must adhere to its internal policies and procedures.

### Staff Training and Delegation of Responsibilities

Only qualified individuals are permitted to perform activities described in this document per the quality terms within the clinical trial agreement signed by each site. In certain instances, the necessary elements of the quality agreement have been incorporated into the site's clinical trial agreement.

Any individual involved in any part of the study must be appropriately delegated those tasks on the delegation log and have appropriate training and/or experience to perform his/her activities. Individuals acting in the lead cell lab staff roles are responsible for ensuring that all other individuals that are performing apheresis collection, packaging, and shipping activities are appropriately trained, and their training is documented.

A training record describing each individual's qualification must exist and be available for inspection by the sponsor's representatives and regulatory agency inspectors.

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

#### **Good Documentation Practices**

- Documentation is required to reconstruct the events and activities of the study. In this study, documentation will be accomplished through, but not limited to, the use of forms, logs, facsimiles, and correspondence, or maintained directly within an Interactive Response Technology (IRT).
- Any other means required to achieve the above goal (e.g., worksheets) may be used to ensure proper documentation of activities. All such documentation must be retained.
- Blank forms required for use in the procedures, as instructed in this manual, are provided in the site IP binder.
   If you require help in using these forms, contact the SM.
- When completing study documents and forms, please note the following:
  - Make entries only with a permanent (indelible) pen.
  - Corrections must be made so as not to obliterate the original text. This is done by drawing a single line through the error and printing a legible correction as close to the error as possible. Original entries should not be erased, or otherwise obliterated (e.g., by using correction tape or fluids).
  - All corrections must identify who made the correction, be dated, and must also include an explanation (e.g., typo, incorrect date).
  - Abbreviations or codes may be used for standard explanations, provided a list of these is included with the documentation.
  - For additional form-specific instructions refer to the form completion instructions and/or discuss with the SM.
  - All spaces for entries including headers (e.g., subject ID number) must be completed. If a field should be left blank, draw a line through it.
  - Do not use "ditto" (or its equivalents) for repeated identical entries. Unless specifically directed in the completion instructions, do not use check marks or "x"s.
  - Do not add any information that is not specifically requested on the form. If for any reason there is a need to adapt the forms and/or include additional information, contact the SM for the proper method.
  - The date format is: DD-MMM-YYYY (e.g., 01-JAN-2010)
  - Time should be expressed in a 24-hour (or military) format (i.e., 8:30 am is recorded as 0830 and 8:30 pm is entered as 2030); otherwise, ensure that am or pm is designated.

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## Records

#### **Good Documentation Practices**

The site is expected to establish and maintain a records retention schedule for the identification, completion, checking, controlled storage, protection, retrieval, retention, and destruction of active and inactive records in accordance with the sponsor requirements and the Quality Agreement.

Records shall be stored so that they can be accurately, completely, and consistently retrieved and/or accessed in a timely manner. The records shall be stored and maintained as to prevent damage or deterioration for the record retention period.

The site shall ensure that records are accessible to the sponsor during health authority inspections, audits and site visits.

The record retention schedule shall enable tracking of retention times for all records, including inactive stored records.

Examples of records are provided below:

- · Chain of custody and chain of identity forms
- · Production records
- · Equipment cleaning
- · Quality Assurance /Quality Control records
- Quality system records (Deviations, CAPA, Change Control)
- · Complaints files
- · Training records
- · Validation records
- Engineering Change Orders/Notifications

The site shall follow the applicable retention period for the minimum period as outlined in the protocol and clinical trial agreement and applicable legal and regulatory requirements.

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOTHISOTICOOTHISOTI	Document No.:	TV-eFRM-13010	Version:	3.0

Abbreviat	ions
APH	Apheresis
AWB	Air Waybill
CAR-T	Chimeric Antigen Receptor - T cell
eCRF	Electronic Case Report Form
coc	Chain of Custody
COI	Chain of Identity
CPC	Cryopreservation Center
CRYO	Cryopreservation
сѕом	Clinical Supply Operations Manager
DIN	Donation Identification Number
IP	Investigational Product
IPPI	Investigational Product Preparation Instruction
ISBT	International Standard for Blood Transfusion
IRT	Interactive Response Technology
LN <sub>2</sub>	Liquid Nitrogen
MFG	Manufacturing
MNC	Mononuclear Cell
PI	Principal Investigator
PPE	Personal Protective Equipment
PQC	Product Quality Complaint
QP	Quality Person
REC	Receipt at Site
RTN	Return of IP
SEC-DIS	Single European Code Donor Identification Sequence

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

SHIP	Shipment from Site
SIPPM	Site Investigational Product Procedures Manual
SM	Site Manager
TIC	Thermal Isolation Chamber
TOR	Temperature Out of Range
TRN	Transfer to Shipment Facility
VIP	Vacuum Insulated Panels
WBC	White Blood Cell

Key definitions	
MNC, Apheresis	A cell product containing a high percentage of mononuclear cells (MNCs) obtained by apheresis. Also known as apheresis material.
Consignee kit pouch	Used by the sponsor when shipping the empty shipper back to the courier upon receipt of the cryopreserved apheresis material. Information is included here only for reference.
Shipper kit pouch	Used when shipping cryopreserved apheresis material back to the sponsor.
Cryogenic containment envelope pouch	Envelope containing absorbent material capable of absorbing 100 ml of fluid used as a secondary containment.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
	Document No.:	TV-eFRM-13010	Version:	3.0	



# Module 1: Pre-Collection

Version: 5.0

Date: 12-APR-2024

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOIIISOII &OOIIISOII	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 1: Table of Contents**

- 1.1 Study Supplies
- 1.2 Pre-Collection Activities (All Subjects)

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 1: Revision History**

This is a controlled document.

VERSION DATE (DD-MON-YYYY)	SECTION(S) CHANGED	DESCRIPTION OF CHANGE(S)
01-Mar-2021	Initial Document	
05-Jul-2021	1.2	Updated wording outlining slot reservation process, randomization and Vineti ordering Included statement on re-treatment per protocol
10-Mar-2022	Module 1	Updated CSOM email to: Central.Scheduling@ITS.JNJ.com
	1.2.1 & 1.2.5	Reference to CQUENCE clinical trial portal added
28-Mar-2022	Module 1	Formatting changes
06-Mar-2023	1.2.1	Updated details on the importance of data entered for scheduling and criticality of slot approval process
	1.2.5	Removed Vineti steps
12-APR-2024	1.1	Added IDM testing kits for EEA & ISR in ancillary supplies
	1.2	Minor wording updates & numbering of steps

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOTHISOTICOOTHISOTI	Document No.:	TV-eFRM-13010	Version:	3.0	

### 1.1 Study Supplies

This provides details of study supplies that will be supplied by the sponsor.

#### **Materials**

Investigational Product (IP): JNJ-68284528 (ciltacabtagene autoleucel)

Refer to the protocol for a description of the IP.

Refer to the Material Data Safety Sheet in the Site IP binder for information about the IP.

#### Other Medications:

Refer to the protocol and non-JNJ-68284528 SIPPM for a description of other medications used in the study.

#### **Ancillary Supplies:**

See below table for ancillaries initially provided by the sponsor for use in activities documented in the CTPPM. All supplies related to packaging and shipment of MNC, apheresis material and receipt of IP are contained in the Shipments section of the CTPPM.

Refer to the IP Preparation Instructions in the Site IP Binder for ancillary materials needed for investigational product preparation/administration.

Ensure that an adequate inventory of the below supplies is maintained, and the sponsor is alerted of any supplies needed in accordance with the below lead times below. If additional ancillary supplies for apheresis are needed, email Central.Scheduling@ITS.JNJ.com and specify which supplies and quantities are required.

Ancillary	Provided By	Process Utilized In	Storage Conditions	Lead-times
Bulk Label Supply: Labels, Self- laminating cards & zip ties	Sponsor	Module 2 Apheresis	Room Temperature	3 weeks
Wire Cutters	Sponsor (if required)	Module 6 Shipment Receipts	Room Temperature	3 weeks

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## **1.2 Pre-Collection Activities (All Subjects)**

This section outlines the steps for reserving a manufacturing slot for the production of IP per subject.

.

Step	umentation & Patient Verification  Task	Responsibility
1.2.1	Slot Reservation	Clinical Site
	The slot reservation request process will start during the pre-screening period to reserve and obtain an approval of a slot <b>prior to consent</b> of a potential subject.	
	<ul> <li>A slot request must be submitted once a potential subject has been identified.</li> <li>Submitting a slot request means cryopreservation and manufacturing capacity are checked for the subject.</li> </ul>	
	<ul> <li>The site must submit a request for apheresis date approval to the sponsor for a specific potential subject in the CQUENCE Clinical Trials portal. If the portal cannot be utilized, a pdf slot Reservation form can be emailed to <a href="mailto:central.scheduling@its.jnj.com">central.scheduling@its.jnj.com</a>. Site personnel can reach out to the sponsor (SM) for a blank copy of the paper slot reservation.</li> </ul>	
	<ul> <li>This slot request must be submitted at least two (2) business days (but preferably one</li> <li>(1) week) prior to the expected consenting date.</li> </ul>	
	<b>IMPORTANT:</b> Subject MUST not be consented or screened until the slot has been approved by the Sponsor.	
1.2.2	The sponsor will review the slot reservation request and approve or reject the slot. If approved, approval will be provided to the site along with the projected date for manufactured ciltacabtagene autoleucel to be onsite.	Sponsor
1.2.3	Screening	Clinical Site
	Once the slot has been approved, the site may proceed with collecting informed consent and screening.	
	At the time of signing consent, complete the Screening transaction in IRT (see IRT site user Manual).	
	A unique 13-digit subject ID will be generated on completion of the IRT transaction.	
	Example: N05US10001001 (10-digit site number + 3-digit subject code)	
1.2.4	Eligibility Confirmation	Clinical Site
	<ul> <li>Enter all pertinent subject screening data in the eCRF.</li> <li>Then, submit the Eligibility Approval Request transaction in IRT, requesting sponsor approval.</li> </ul>	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Doc	Documentation & Patient Verification					
Step	Task	Responsibility				
1.2.5	<ul> <li>Approve enrollment based on screening data entered in eCRF after all queries have been resolved and all data has been appropriately updated in the eCRF.</li> </ul>	Sponsor				
1.2.6	Randomization (only applicable to protocols requiring randomization)	Clinical Site				
	<ul> <li>Once eligibility is confirmed, randomize the subject via IRT on the pre-agreed randomization date <u>only.</u></li> </ul>					
	NOTE: If an additional apheresis is requested by sponsor, follow the steps outlined in 'Pre-collection activities (All subjects)'.					
1.2.7	Apheresis Scheduling In case of changes to the date of apheresis after slot approval, this needs rescheduling via the CQUENCE Clinical Trials portal. If further discussion is needed beyond rescheduling the date, contact: <a href="mailto:central.scheduling@ITS.JNJ.com">central.scheduling@ITS.JNJ.com</a>	Clinical Site				
1.2.8	Approve any updated apheresis date request from the site in alignment with available capacity.	Sponsor				
	<ul> <li>Per the approved date of apheresis for the assigned subject's slot, schedule the delivery of the empty CREDO CUBE shipping container to the clinical site.</li> </ul>					

# **MODULE 1 COMPLETED**

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0	



# Module 2:

# Apheresis & Cell Management

Version: 5.0

Date: 12-APR-2024

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 2: Table of Contents**

- 2.1 Apheresis Labeling
- 2.2 Apheresis Collection
- 2.3 Cell Management

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 2: Revision History**

This is a controlled document.

VERSION DATE (DD-MON-YYYY)	SECTION(S) CHANGED	DESCRIPTION OF CHANGE(S)		
01-Mar-2021	Initial Document			
05-Jul-2021	2.3	<ul> <li>Updated definitions and naming conventions for all regions Apheresis collection section updated with the following requirements.</li> <li>New apheresis target collection added and changed from MNC to WBC</li> <li>Note clarify anticoagulant volume is applicable to product</li> <li>Note added for recommended storage temp and transport temperature</li> <li>Added recommendation for plasma to be added to collection bag for shipment</li> <li>Added recommendation to take mid-point samples</li> <li>Removed recommendations for whole blood to be processed</li> </ul>		
10-Mar-2022	2.1.2, 2.2.2	Added statement for apheresis bag label expiration date & time to meet requirements for Janssen starting material and storage temperature requirements		
	2.2.3, 2.2.4	Deleted central printed labels option added new instructions for manual label completion		
	2.3.1	Added IDM instructions for KOR; Changed IDM testing requirement for AUS from 7 days to 30 days		
	2.3.2	Added Vineti steps for capturing IDM sample		
	2.3.6, 2.3.7, 2.3.9	Updated instructions for apheresis collection and added instructions to store the apheresis product in a monitored refrigerator or intermediary transport at 2-8°C until the time of shipment occurs		
28-Mar-2022	Module 2	Formatting changes and deleted 13 and 21 digits when mentioned for unique identifier		
06-Mar-2023	2.1.1, 2.1.3	Changed supplemental label to sponsor label		
	2.1.2	Edited requirements for site bag label		
	2.1.3, 2.1.4	Added instructions critical to hang tag completion between shipper and apheresis label		
	2.2	Removed section related Vineti		

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONAOOMISON	Document No.:	TV-eFRM-13010 Version: 3.0		
	2.3	Updated to section 2.2		
	2.2.2	Adjusted wording for using institution SOPs Added recommendation for quantity of whole blood processed		
	2.2.3	Added clarification to capture quantity of heparin used with ACD-A on COC/COI form		
	2.2.4	Added autologous to clarify adding plasma		
	2.2.7	Updated wording of apheresis product to apheresis material		
	2.2.9	Removed min collection requirement 2x10e9		
	2.4.1	Added for Israel sites only to enter patient ID specific to requirement from MoH		
,	2.4.2	Adjusted wording for possible second collection		
12-APR-2024	2.1.2	Further details included & re-ordered label items		
	2.2	Added IDM requirements for the UK		
	2.2.1	Added IDM results communication method for South Korea		
	2.2.4	Removed the addition of 50mL autologous plasma to the final collection bag if less than 100mL		
	2.2.7	Clarified that only one sampling bulb may be used by the clinical site		
	2.1.2, 2.3.1	Updated wording for unique identifier of apheresis collection		
	Module 2	Replaced NA_APH form with new NA_APH-TRN form		
	Module 2	Updated wording for MBOX system & responsibility		

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 2.1 Apheresis Labeling

This section describes the labeling and forms to manage the COC/COI of the Apheresis material.

Lak	pels	
Step	Task	Responsibility
2.1.1	Bulk Label Supplies Binder	Sponsor
	Your site will have been provided a bulk label supplies binder during site initiation, including the following materials per study:	
	Sponsor-provided apheresis labels	
	Sponsor-provided shipper labels	
	Self-laminating cards	
	• Zip ties	
2.1.2	APHERESIS – Site bag label	Clinical Site
	Print apheresis bag labels as per site process. It is recommended to follow ISBT 128 guidelines and local requirements.	
	The site apheresis bag label must include, at a minimum, the following elements:	
	Type of collection: MNC, Apheresis	
	Date and time of apheresis end of collection (including time zone)	
	Volume of apheresis collection	
	Volume of anti-coagulant in the collection bag	
	Subject Name (including middle name or initial as documented in medical records)	
	Date of Birth	
	Unique identifier for apheresis collection:	
	<ul> <li>DIN where applicable for countries in NA</li> </ul>	
	• Storage temperature 2-8°C. The storage temperature on the apheresis bag label should be consistent with the sponsor label requirements.	
	Any required warnings per local standards & regulations	
	If the apheresis expiration date & time are included in the apheresis bag label, this must follow the requirements for sponsor starting material expiration time of <b>thirty-two (32) hours</b> from end of collection time.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Lak	pels control of the c	
2.1.3	APHERESIS – Sponsor label	Clinical Site
	The sponsor-provided apheresis label is pre-printed with the sponsor name and a description. Complete the following information on the sponsor label:	
	<ul> <li>Site Number</li> <li>Subject Number</li> <li>DIN or Apheresis ID</li> <li>Date of collection</li> </ul> After completing all sections of the sponsor apheresis label, ensure that information is accurate and complete, by performing a double-check. Place the label onto the self-laminating card and attach the self-laminating card to the	
	apheresis bag using the zip tie provided by the sponsor.	
	Refer to section 2.1.5 for instructions.	
2.1.4	SHIPPER – Sponsor Label	Clinical Site
	The sponsor-provided shipper label is pre-printed with the sponsor name and a description. Complete the following information on the label:	
	Site Number	
	Subject Number	
	DIN or Apheresis ID	
	After completing all sections of the sponsor shipper label, ensure that the information is accurate and complete by performing a double-check. The shipper label is included with the apheresis material shipment to the CPC.	
	Specific instructions for the shipper label are outlined in Module 5.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOIIISOII &OOIIISOII	Document No.:	TV-eFRM-13010	Version:	3.0	

#### 2.1.5 Instructions for Use of self-laminating card with Sponsor-provided Apheresis Label

Step 1	Step 2	Steps	3.1 – 3.4	Step 4
Bulk label supplies binder will contain:  • Sponsor apheresis Label to attach to the bag	2.1 Fill out the necessary information on the label.	3.1 Lift the top flap of the self-laminating card.	3.2 Place the label onto the self-laminating card.	Secure the self-laminating tag and label via zip tie to the collection bag.
<ul> <li>A self-laminating card to place the label onto</li> <li>A zip tie to attach the label to the bag</li> </ul>	2.2 Peel the paper off the label to expose the adhesive side.	3.3 Remove the paper on the self- laminating card.	3.4 Laminate and seal the labels onto the self- laminating card.	

Once completed, proceed to section 2.2 Apheresis collection.

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## 2.2 Apheresis Collection

Mononuclear cells (MNCs) will be collected from each subject via apheresis for use in the manufacturing of the autologous cellular product.

Aph	eresis collection	
Step	Task	Responsibility
2.2.1	MNC, apheresis collection should be performed according to the site's standard operating procedures following instructions from the sponsor:  - Target cell count: 9 x 10 <sup>9</sup> Total WBC, aka Total Nucleated Cells (TNC), containing a high % of MNC.  - Acceptable range: 6 to 12 x 10 <sup>9</sup> Total WBCs.	Clinical Site
	<u>NOTE:</u> Approximately 9-12 liters of whole blood should be processed. The blood volume processed is dependent on the protocol apheresis parameters, subject's weight, and medical status.	
2.2.2	The use of Anticoagulant Citrate Dextrose solution, solution-A (ACD-A) or ACD-A plus heparin is permissible.  If both ACD-A and heparin are used; the quantity of heparin should be added to comment	Clinical Site
	section of the <b>NA_</b> APH-TRN COC/COI form. Use of heparin alone is not permitted.  NOTE: The anticoagulant volume (mL) to be captured on the NA_APH-TRN COC/COI form, should be the volume of anticoagulant in the apheresis collection bag.	
2.2.3	Strip the tubing and leave a minimum of 15 cm (6 inches) of tubing when sealing off the apheresis bag from the collection kit.	Clinical Site
2.2.4	Seal tubing using triple weld/seal technique.	Clinical Site
2.2.5	The apheresis material must be transferred and placed into a 2-8°C shipper within 60 minutes of the collection end time.	Clinical Site
	If more time is required, store the apheresis material in a monitored refrigerator or intermediary transport at 2-8°C until the time of shipment occurs.  NOTE: If the apheresis material is stored overnight at the clinical site, provide the sponsor	
	with a copy of the temperature data report. Upload a copy of this report to MBOX.	
2.2.6	It is recommended to perform a WBC count at the midpoint of the collection to ensure the target cell number (9 x 10 <sup>9</sup> Total WBCs) is reached and to minimize patient apheresis time.	Clinical Site
	When collecting midpoint sample, do not spike the bag. Use only one of the available sampling bulbs and aseptic technique.	
2.2.7	IMPORTANT: If the minimum total WBCs are not collected on the first attempt, the sponsor may request a second collection. Each apheresis collection should be performed with the goal of achieving 9 x $10^9$ Total WBC target.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 2.3 Cell Management

Once apheresis is complete, the collection is referred to as starting material, ready to be sent for manufacturing into IP.

Cell	Management	
Step	Task	Responsibility
2.3.1	Once the unique identifier is assigned to the donation, enter the following details in IRT on the day of collection as soon as the unique identifier is available: This is <u>critical</u> information required for packing the apheresis material and for the creation of the cryopreservation labels.	Clinical Site
	Refer to IRT manual for instructions.	
	<ul> <li>Subject Name (to include middle name or initial as documented on medical records and site bag label)</li> </ul>	
	Date of Birth	
	Unique identifier for apheresis collection:	
	<ul> <li>DIN where applicable for countries in NA</li> </ul>	
	<ul> <li>Subject weight in kg on day of apheresis. IMPORTANT: must be rounded to 1 decimal point, i.e., 59.0 or 59.5 kg</li> </ul>	
	NOTE: All subject identifiers & weight entered in IRT should be double-checked for accuracy and should match entries on all source documents and labels.	
2.3.2	If a $2^{\text{nd}}$ apheresis collection is requested by the sponsor, perform an "Apheresis Collection" transaction in IRT.	Clinical Site

ඟ	COC/COI ACTIONS:	Responsibility
	Complete the Apheresis Chain of Custody/Chain of Identity Form (see NA_APH-TRN) and enter all applicable data in the eCRF.	Clinical Site
£	Upload a signed copy of this form to MBOX on the same day.	Clinical Site



If the apheresis material will be packed and shipped directly from the collection center, proceed to **Module 5** 'packing and shipment'.

If the apheresis material will be transferred to cell lab or shipment facility to be packed and shipped or for onsite cryopreservation, proceed to **Module 3 'Cell transfer'.** 

# **MODULE 2 COMPLETED**

Johnson&Johnson	Cell Therapy Product Procedures Manual				
oomison & oomison	Document No.:	TV-eFRM-13010	Version:	3.	.0



Version: 5.0

Date: 12-APR-2024

This module is only applicable to sites who perform transfer of apheresis material from collection location to be packed at a different location.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 3: Table of Contents**

3.1 Transfer of apheresis material to cell processing lab

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOTHISOTICOOTHISOTI	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 3: Revision History**

#### This is a controlled document.

VERSION DATED DD-MON-YYYY	SECTION(S) CHANGED	DESCRIPTION OF CHANGE(S)
01-Mar-2021	Initial Document	
05-Jul-2021	3.1	Minor updates to regional definitions and abbreviations  Note added for overnight storage of the apheresis product
10-Mar-2022	3.1.1	Changed wording to: store in a monitored refrigerator or intermediary transport at 2-8°C until the time of shipment occurs
28-Mar-2022	Module 3	Formatting changes
06-Mar-2023	3.1	Updated wording to refer to apheresis material and remove references to Vineti
12-APR-2024	Module 3	Replaced NA_TRN form with new NA_APH-TRN form Updated wording for MBOX system & responsibility

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## 3.1 Transfer of apheresis material to cell processing lab

Collected apheresis material when is transferred to the site's cell processing lab or other facility for subsequent packing and shipment to the CPC or for cryopreservation.

Trar	Transfer of apheresis material to cell processing lab				
Step	Task	Responsibility			
3.1.1	Upon completion of collection, follow the sites internal procedures to transfer the apheresis material to the cell processing lab or other shipment facility.	Clinical Site			
	• Apheresis material must be transferred and placed into 2-8°C shipper within one hour (60 minutes) of the end of collection. If more time is required prior to the transfer, store the apheresis material in a monitored refrigerator or intermediary transport at 2-8°C until the time of shipment occurs.				
	NOTE: If the apheresis material is stored overnight at the clinical site, provide the sponsor with a copy of the temperature data report. Upload a copy of this report to MBOX.				
3.1.2	The chain of custody of the apheresis material must be documented in the required section of the COC/COI form (NA_APH-TRN).	Clinical Site			

ලා	MANUAL COC/COI ACTIONS:	Responsibility
	Document the chain of custody from apheresis unit to Cell laboratory or shipment facility on the Apheresis Chain of Custody/Chain of Identity form (see NA_APH-TRN)	Clinical Site
£	Upload a signed COC/COI form to the sponsor MBOX on the same day.	Clinical Site

## **MODULE 3 COMPLETED**

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0	



## Module 4:

# **Cryopreservation Procedure**

Version: 5.0

Date: 12-APR-2024

This module is only applicable to sites who perform on-site cryopreservation.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## **Module 4: Table of Contents**

- 4.1 Cryopreservation: Labeling
- 4.2 Cryopreservation and LN<sub>2</sub> Storage

**Cryopreservation: Shipping** 

- 4.3 Communication Plan with Site, Courier and Sponsor
- 4.4 Review of Packing Materials
- 4.5 Instructions for Receipt of Empty LN<sub>2</sub> Shipper
- 4.6 Packing of cryopreserved apheresis material into LN<sub>2</sub> Shipper

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 4: Revision History**

This is a controlled document.

VERSION DATE DD-MON-YYYY	SECTION(S) CHANGED	DESCRIPTION OF CHANGE(S)
01-Mar-2021	Initial Document	
05-Jul-2021	4.1	Minor updates to regional definitions and abbreviations
	4.2	Updates to shipper label applied to batch record
	4.5	Updates to Vineti steps
	4.6	Update wording for temperature excursion and CSOM as main point of contact
		Updated wording for IRT notification and temperature excursions
		New Cryogenic Containment Pouch added
10-Mar-2022	4.1.1 & 4.1.3	Updated labelling numbers for two bag process and corrected to read apply cryopreservation label directly to the cryo bag
	4.3.3	Added note: Site nor local team has access to the EVO-IS system temperature data
	4.4.2, 4.5.4, 4.6.2, 4.6.6 & 4.6.11	Updated packing material 3-Piece Packing Solution: Poly bags, Tyvek bags, and absorbent pads or 1-Piece Packing Solution: CryoPort envelope and foam dunnage
28-Mar-2022	Module 4	Formatting and administrative changes
06-Mar-2023	4.1, 4.2	Removed local from cryopreservation process Adjusted wording to refer to apheresis material, cryopreserved apheresis material and revised the required cryopreservation labels Removed references to Vineti
	4.1.4	COC/COI form referenced 'XX_CRY' is now a global form and the name of form is now referred to as 'CRY' (an abbreviation of the term cryopreservation)
	4.3	Adjusted wording to refer to apheresis material, cryopreserved apheresis material
	4.4, 4.5	Edited outer shipper to align with other modules and added instructions for QR code
	4.6	Removed 3-piece packing solution and removed Vineti steps
	4.6.1	COC/COI form referenced 'XX_SHIP_CRYO' is now a global form and the name of form is now referred to as 'SHIP_CRYO' (an abbreviation of the term cryopreservation)
12-APR-2024	4.1.2	Clarified that 2 shipper labels are required for cryopreserved apheresis material import to the USA

Johnson&Johnson	Cell Therapy Product Procedures Manual				
JOHNSON	Document No.:		TV-eFRM-13010	Version:	3.0
4	4.3.4 Updated charged shipper arrival time				
4	4.5.5, 4.5.7, 4.6.4				
4	4.6.2	Added details on shipping materials expected			
4	4.4, 4.5, 4.6	Removed references to obsolete videos Updated wording for MBOX system & responsibility			

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 4.1 Cryopreservation: Labeling

This section is only applicable to sites that have completed a technical transfer of the sponsor cryopreservation method and these steps must be followed alongside the sponsor batch record.

Steps	Task	Responsibility
4.1.1	The following labels will accompany the apheresis material to the cell lab:	Clinical Site
	One (1) sponsor apheresis label attached to the apheresis material bag	
	One (1) site apheresis bag label affixed to the apheresis bag	
	Create subject specific sponsor cryopreservation labels with the sponsor approved label templates.	
4.1.2	Prepare the following labels that will accompany the cryopreserved apheresis material inside the LN <sub>2</sub> shipper:	Clinical Site
	• One (1) or Two (2) sponsor shipper label(s). When imported into the USA, a second shipper label must be included in the clear packing envelope on the outside of the LN <sub>2</sub> shipper with AWB.	
	One (1) sponsor shipper label for batch record	
4.1.3	Sponsor cryopreservation labels:	Cell Lab
	Prepare and affix sponsor cryopreservation label directly to the cryopreservation bag.	
4.1.4	Sponsor cassette label:	Cell Lab
	Prepare and affix a sponsor cassette label to each cassette under room temperature conditions 30 MINUTES BEFORE the cassette is placed into the controlled rate freezer, otherwise, the label will not adhere properly to the cassette.	
4.1.5	In the <b>CRYO form,</b> indicate the number of bags used for cryopreservation. Then apply each label(s) to the cryo bag and corresponding cassette	Cell Lab
4.1.6	Label Reconciliation:	Cell Lab
	Once all labels have been applied to the bags and cassettes, <b>complete the Batch Record</b> to document which labels have been used, damaged and/or destroyed.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
JOHNSON & JOHNSON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 4.2 Cryopreservation and LN<sub>2</sub> Storage

This section is only applicable to sites that are utilizing an on-site cryopreservation lab and should be followed alongside the sponsor batch record.

Cryo	preservation and LN₂ Storage	
Steps	Task	Responsibility
4.2.1	Cryopreservation and storage of the apheresis material should be performed in the site cell lab per the sponsor apheresis cryopreservation batch record.	Cell Lab
	<ul> <li>Follow the sponsor apheresis cryopreservation batch record for instructions on cell processing and cryopreservation of the apheresis material.</li> </ul>	
	<ul> <li>The batch record outlines the bill of materials required for cell processing and cryopreservation referenced in the section related to study supplies.</li> </ul>	
STOP	IMPORTANT: Next steps below need to be performed as quickly as possible. It is critical to pack the cassette(s) into the LN₂ freezer quickly to avoid thawing of the cryopreserved apheresis material.	Cell Lab
4.2.2	<ul> <li>Upon completion of the controlled rate freezing process, the cryopreserved apheresis material must be stored at ≤ -120°C in the vapor phase of liquid nitrogen storage system.</li> <li>Remove cassette with cryopreserved apheresis material from the controlled rate freezer (one at a time) and place each cassette inside LN₂ tank.</li> <li>NOTE: Transfer times must be ≤3 minutes.</li> </ul>	Cell Lab

ര	COC/COI ACTIONS:	Responsibility
	Complete the CAR-T Cryopreservation Chain of Custody/Chain of Identity Form (see CRYO)	Cell Lab
£	Upload a signed copy of the COC/COI form to the sponsor MBOX on the same day.	Cell Lab

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Johnson	Document No.:	TV-eFRM-13010	Version:	3.0	

## 4.3 Cryopreservation Shipping: Communication Plan with Site, **Courier and Sponsor**

There are two types of shipments related to the packaging and shipment of cryopreserved apheresis material to the manufacturing facility.

- Shipment of charged empty LN2 shipper to the site
- Shipment of cryopreserved apheresis material from clinical site to the manufacturing facility

Step	Task	Responsibility
4.3.1	The sponsor will initiate order pick up with the courier.	Sponsor
4.3.2	The courier will issue an automated pre-alert/order confirmation to the site.	Courier
	The notification will reference the subject number to track and trace the shipment from clinical site to the manufacturing facility.	
	<ul> <li>The notification will also reference the Air Waybill (AWB) for the shipment.</li> <li>NOTE: a print-out of the same AWB will be provided in the shipper kit pouch within the shipper.</li> </ul>	
4.3.3	The courier will send one notification to the clinical site contact(s) prior to delivery of the empty charged shipper. The notification will be:	Courier
	The day of delivery, within 1 hour prior to delivery. This is a geofence notification and will trigger when the shipment is within a 5-mile radius of the clinical site.	
	NOTE: The site or sponsor local team does not have access to the EVO-IS system temperature data.	
	<ul> <li>Any delays in shipment will be communicated by the courier via e- mail to the designated site contact.</li> </ul>	
4.3.4	The charged shipper will arrive at the site in the morning at the agreed local time to pack the cryopreserved apheresis material.	Courier
4.3.5	The sponsor will coordinate with the courier to return that afternoon to pick up the cryopreserved apheresis material at an agreed local time for delivery to the manufacturing facility.	Sponsor
1	IMPORTANT Notify CSOM via email: Central.Scheduling@ITS.JNJ.com and copy your SM if the packed shipper will not be ready for pick-up by the courier by agreed local time.	Cell Lab

Johnson&Johnson	Cell Therapy Product Procedures Manual			
ooninson & ooninson	Document No.:	TV-eFRM-13010	Version:	3.0

# 4.4 Cryopreservation Shipping: Review of Packing Materials

Revi	ew of Packing Materials	
Step	Task	Responsibility
4.4.1	The following tools should be utilized in preparation for packing the LN <sub>2</sub> shipper:  Cryogloves Safety glasses Wire cutter  NOTE: Adhere to any additional site requirements for PPE when handling cryopreserved products and equipment.	Cell Lab
	Do not discard any contents or packaging materials until you have read these instructions.	
4.4.2	Upon the receipt of shipper, you will find the following components inside the outer shipper case:	Cell Lab
	• LN <sub>2</sub> shipper (Savsu DV-10)	
	Shipper Kit pouch (inside the pouch within the shipper case)	
	Consignee Kit pouch (inside the pouch within the shipper case)	
	The <b>shipper Kit Pouch</b> is used when shipping cryopreserved apheresis material to the sponsor. The <b>shipper Kit Pouch</b> includes:	
	<ul> <li>One (1) red tamper evident seal (for use on one side of the LN<sub>2</sub> shipper lid, number should match the AWB)</li> </ul>	
	One (1) red tamper evident seal (for use on cassette rack)	
	One (1) zip tie (for use on the outer shipper case lid)	
	One (1) zip tie (for use on one side of the LN₂ shipper lid)	
	1-Piece Packing Solution: Cryogenic containment envelope pouch and foam dunnage	
	One (1) clear side packing envelope	
	AWB for shipment	
	The <b>consignee Kit Pouch</b> is used by the sponsor when shipping the empty shipper back to the courier upon receipt of the apheresis cryopreserved material. Information is included here only for reference.	
	1 zip tie (for use on the outer shipper case)	
	AWB for return shipment of empty shipper	
	<b>Inside the shipper,</b> there will be an empty cassette rack. This is used to store and secure the cassettes inside the shipper during transport.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Step
STOP

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0	

# **4.5** Cryopreservation Shipping: Instructions for Receipt of Empty LN<sub>2</sub> Shipper

The following are step-by-step instructions for receipt of the empty  $LN_2$  shipper in anticipation of packing of the cryopreserved apheresis material.

Inst	ructions for Receipt of the Empty LN <sub>2</sub> Shipper	
Step		Responsibility
4.5.1	The shipper will arrive inside an outer corrugated case. The outer corrugated case includes wheels and luggage handle for ease of transport.	Cell Lab
	<ul> <li>Once the shipper has been transported to the appropriate packaging location, set the shipper upright and lower the luggage handle.</li> </ul>	
	DO NO X-RAY	
4.5.2	The outer corrugated case is secured by buckle straps.	Cell Lab
	Unclip the buckle straps. Open the outer corrugated case lid.	
	DO NOT X-RAY	

Johnson & Johnson


Document No.:

Cell Therapy Product Procedures Manual

TV-eFRM-13010 Version: 3.0

Inst	ructions for Receipt of the Empty LN <sub>2</sub> Shipper	
Step	Task	Responsibility
4.5.3	The outer case shipper lid is secured by a single zip tie through the zipper pulls.  • Cut and discard the zip tie then unzip the outer case lid.	Cell Lab
	NOTE: The site will need to use wire cutters (these are NOT included in the shipment).	
4.5.4	Lift the shipper case lid.	Cell Lab
	Verify that the pouch within the outer case contains the shipper kit pouch and consignee kit pouch—which are labeled.	
	<ul> <li>Remove the shipper kit pouch and its materials. These materials will be used for packing the cryopreserved apheresis material.</li> </ul>	
	Pock ** Prock ** Proc	
	NOTE: Leave the consignee kit pouch inside the pouch within the outer case.	

Johnson&Johnson	Cell Th	erapy Product Pro	ocedures Manual		
OUTHSUITAOUTHSUIT	Document No.:	TV-eFRM-13010	Version:	3.0	,



Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0		

#### **4.5.6** Confirm if there is any temperature excursion:

- To determine if the temperature is within range, press the light indicator, release & wait for 5 seconds on the DV-10 lid. The indicator will emit a light. A steady light indicates that the temperature is within range. You can proceed to the next steps.
- A flashing light indicates a temperature excursion has occurred.
- If no light is present, scan QR code on DV-10 lid with a smart device. Scanning the QR code will direct the user to a web page that displays the last reported payload temperature with the last recorded temperature reading. This QR code should only be used as a BACK UP solution in case the light indicator fails.
- NOTE: The QR code label and the QR code displayed on the web page are correlated
  with the EVO-IS ID. Verify that the EVO-IS ID on the web page display exactly matches
  the QR code label ID and EVO-IS ID on the DV-10 lid. Confirm on the QR code
  temperature snapshot display that the time stamp is current.
- If any of the following occurs, notify CSOM via Central.Scheduling@ITS.JNJ.com and copy the SM:
  - A flashing light indicating a temperature excursion has occurred.
  - Temperature light indicator is not functioning (does not turn on).
  - There is any ID mismatch, concerns regarding the QR code, and/or an out-ofrange temperature.

#### **Press Indicator**



#### **Light Indicator**



#### Example of QR code and web page display







Cell Lab

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual			
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Step	Task		Responsibility			
.5.7	Inside the shipper kit pouch, there are 2 tamp	per evident seals	Cell Lab			
	Tamper evident seal with "SECURED" a	and serial number listed				
	Tamper evident seal with "RACK" listed	I				
	Verify the tamper evident seal number (SEAL#) listed on the AWB matches the tamper					
		L#) listed on the AWB matches the tamper				
	Verify the tamper evident seal number (SEAI	L#) listed on the AWB matches the tamper  World Courier				
	Verify the tamper evident seal number (SEAl evident seal from the shipper kit pouch.	World Courier To (CONSIGNEE)				
	Verify the tamper evident seal number (SEAI evident seal from the shipper kit pouch.  QuickSTAT  Stat U.S. (718) 995-30 U.K. +44 France +33	World Courier				
	Verify the tamper evident seal number (SEAI evident seal from the shipper kit pouch.  QuickSTAT  Stat U.S. (718) 995-31 U.K. +44 France +33	World Courier  To (CONSIGNEE)  Name Telephone				

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

# 4.6 Cryopreservation Shipping: Packing of cryopreserved apheresis material into the LN<sub>2</sub> Shipper

The following are step-by-step instructions for packing the cryopreserved apheresis material into the LN<sub>2</sub> shipper. **REMINDER:** Ensure all necessary PPE is on before the next steps.

Pac	king of cryopreserved apheresis material into the LN <sub>2</sub> Shipper	
Step		Responsibility
4.6.1		Cell Lab
4.6.2	Ensure all materials in the shipper kit pouch are removed and staged for the packing:  - AWB  - Cryogenic containment envelope pouches (2-4)  - Foam dunnage (2-4)  - Zip ties (x2)  - 2 Tamper evident seals: "RACK" & a numbered seal	Cell Lab
	POCK Name Part And Pa	



<u>IMPORTANT</u>: The next steps need to be performed as quickly as possible. It is critical to avoid thawing of the cryopreserved apheresis material as the cassette(s) are packed into the shipper. Place all packing materials and shipper as close as possible.

### Packing of cryopreserved apheresis material into the LN2 Shipper

StepTaskResponsibility4.6.3Ensure the ports of the cryopreserved apheresis material bag are orientated towards the top of the cassette with the locking hinge.Cell Lab





Cryogenic containment envelope pouch:

- 1) Pre-fold over the scored line shown by the arrow. The pre-fold may fold over the adhesive seal cover.
- 2) Insert the cassette with the locking hinge toward the top and push completely down past the adhesive seal into the cryogenic containment envelope pouch. Ensure the cassette is not behind the adhesive seal.
- 3) Peel off adhesive strip cover on top flap.
- 4) Peel off adhesive strip cover on the envelope pouch.









- 5) a. Seal the cryogenic containment envelope pouch. Ensure to fold flap along prefolded scored line.
  - b. Start sealing from center of pre-fold and work out to the sides. Seal must not have any wrinkles or gaps.
- 6) Fold tabs around seal with pressure. Tabs must be sealed as close as possible to the envelope.








**Example of packed cassette** 



Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOTHISOTIQUOTHISOTI	Document No.:	TV-eFRM-13010	Version:	3.0	



Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison	Document No.:	TV-eFRM-13010	Version:	3.0	

Step	Task	Responsibility
4.6.5	Begin completing SHIP_CRYO Site Shipment Form for Chain of Custody/Chain of Identity Form.	Cell Lab
4.6.6	Remove the shipper lid and lift the cassette rack.	Cell Lab
4.6.7	NOTE: Proper placement of the DV10 Smart Cap when not seated in the dewar body is PROBE SIDE UP on a flat surface. Serious damage to the probe may occur if placed otherwise.	Cell Lab

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Step	Task	Responsibility
4.6.8	Place sealed Cryogenic containment envelope pouch with frozen bag/cassette into the cassette rack. Ensure proper orientation so the locking hinge of the cassette is at the top of the rack.  Place one piece of the foam dunnage on top of the envelope within the cassette rack.	Cell Lab
4.6.9	Return the rack into shipper to prevent warming and close the shipper lid.	Cell Lab

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Johnson	Document No.:	TV-eFRM-13010	Version:	,	3.0

Step	Task	Responsibility
4.6.10	Repeat the packing process for any of the remaining cassettes to be shipped.	Cell Lab
4.6.11	After packing the final cassette, secure the cassette rack with the tamper evident seal. Feed the tamper evident seal with "RACK" through the cassette holes and secure.	Cell Lab
4.6.12	Remove the shipper lid and place the cassette rack (with cryopreserved apheresis material) into the shipper.	Cell Lab
4.6.13	Close the shipper lid, secure the lid, and lower the shipper handle to allow for the closing of the shipper lid after tamper evident seal is attached.	Cell Lab
	SmartCal 18	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Johnson	Document No.:	TV-eFRM-13010	Version:		3.0

l I	ng of cryopreserved apheresis material into the LN2 Shipper	
Step	Task	Responsibility
4.6.14	<ul> <li>Feed the tamper evident seal that contains the word "SECURED" and seal number through the metal hook and lid. As a reminder, this seal number needs to match the seal number listed on the AWB.</li> </ul>	Cell Lab
	<ul> <li>Wrap and secure a zip tie through the lid and around the handle located on the other side of the shipper.</li> </ul>	
	Smal	
4.6.15	Once the shipper lid is secured, place the verified shipper label inside the pouch within the shipper case.  NOTE: Only the consignee kit pouch and the shipper label should remain inside the	Cell Lab
	pouch within the shipper case.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Step	Task	Responsibility
4.6.16	<ul> <li>Obtain the second zip tie provided in the shipper kit pouch.</li> <li>Zip the outer case lid closed and secure by passing the single zip tie through the zipper pulls.</li> </ul>	Cell Lab
4.6.17	Fasten the lid of the outer corrugated case by fastening the buckle straps	Cell Lab
4.0.11	<ul> <li>Remove the existing AWB and place the new AWB (from the shipper kit pouch) into the clear packing envelope.</li> <li>Place the additional shipper label with the new AWB into the clear packing envelope. Applicable to all sites excluding USA.</li> <li>Discard all leftover materials and packaging per site disposal procedures. Discard</li> </ul>	Con Eds
	any remaining items and bags from shipper kit pouch.	



REMINDER: The sponsor will coordinate with the courier to pick up the LN<sub>2</sub> shipper packed with cryopreserved apheresis material from the site at agreed local time. Notify CSOM via email <a href="Central.Scheduling@ITS.JNJ.com">Central.Scheduling@ITS.JNJ.com</a> and copy the SM immediately if there are any constraints for getting this shipment ready at agreed local time.

ര	MANUAL COC/COI ACTIONS:	Responsibility
	Complete the CAR-T Cryopreservation Chain of Custody/Chain of Identity Form (see SHIP_CRYO).	Cell Lab
£	Upload a signed COC/COI form to the sponsor MBOX on the same day.	Cell Lab

# **MODULE 4 COMPLETED**

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOTHISOTIQUOTHISOTI	Document No.:	TV-eFRM-13010	Version:	3.0



Version: 5.0

Date: 12-APR-2024

This module is only applicable for sites shipping apheresis material to CPC.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 5: Table of Contents**

- 5.1 Communication Plan with Site, Courier & Sponsor
- **5.2** Review of Packing Materials
- 5.3 Packing of Apheresis Material into CREDO CUBE Shipper
- 5.4 Courier Pickup of the Packed CREDO CUBE Shipper

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison	Document No.:	TV-eFRM-13010	Version:	3.0	

# **Module 5: Revision History**

This is a controlled document.

VERSION DATE DD-MON-YYYY	SECTION(S) CHANGED	DESCRIPTION OF CHANGE(S)
01-Mar-2021	Initial Document	
05-Jul-2021	5.3	Minor updates to regional definitions and abbreviations throughout document
		Updated image for temptale ultra device
10-Mar-2022	5.1.2, 5.3.1,	Updated instructions for EEA & ISR Removed OBC shipments and updated shipping details for EEA
	5.4.1	Updated statement added for EEA & ISR Credo cube courier arrangements
28-Mar-2022	Module 5	Formatting and administrative changes
06-Mar-2023	5.1	Adjusted wording to refer to apheresis material, aligned wording of temperature monitoring device and courier arrangements
	5.2	Additional packing materials added for all regions
	5.3	Updated packing instructions, removed Vineti steps and added to secure the outer box of credo cube with tape
	5.4	Adjusted wording to refer to apheresis material, removed references to Vineti and added where applicable couriers will provide the AWB when pick up is completed while the courier waits on site.
12-APR-2024	5.1	Edited to provide more concise information: - Couriers unspecified to accommodate for global flexibility Removed 5.1.2; 5.1.3, 5.1.4.
	5.2.1, 5.3	Updated packing and shipment procedure for Japan with removal of SD Collabo courier
	5.2	Clarified that a Real Time Location Monitoring Device RTLM may be included by World Courier in Credo Cube, RTLM should not be removed.
	5.3	Removed references to obsolete videos
	5.2.1, 5.3	Updated wording for the polybag (previously referenced as poly bio bag or bio-pouch)
	5.3.1	Updated pictures for EEA, ISR, Canada, LATAM, AUS, KOR.

Johnson&Johnson		Cell Therapy Product Procedures Manual		
OUTHSUTTAGOTHSUT	Document No.:	TV-eFRM-13010 Version: 3.0		
5.3.8 Added IDM procedure for the UK				
	5.3.10	Updated steps to clarify IDM results packing for AUS		
	5.4	Updated name of XX_SHIP_APH form Updated wording for MBOX system & responsibility		

Johnson&Johnson	Cell Therapy Product Procedures Manual			
Johnson	Document No.:	TV-eFRM-13010	Version:	3.0

## 5.1 Communication Plan with Site, Courier & Sponsor

The apheresis material shipment procedure involves two steps:

- 1. Shipment of empty CREDO CUBE to the site (for packing of apheresis material)
- 2. Shipment of the apheresis material from the clinical site to the CPC

Comi	Communication Plan with Site, Courier & Sponsor				
Step	Task	Responsibility			
5.1.1	The sponsor will coordinate with the assigned shipping courier the pick-up of apheresis material on the day of apheresis.	Sponsor			
	The courier will issue an automated pre-alert/order confirmation to the clinical site referencing:				
	Subject number reference with the AWB for the shipment				
	The CREDO CUBE shipper will arrive at the site at the agreed local time for the packing of apheresis material.				
<b>^</b>	REMINDER: Notify CSOM email <u>Central.Scheduling@ITS.JNJ.com</u> immediately if there are any constraints for getting this shipment ready at agreed local time.	Clinical Site			

Johnson&Johnson	Cell Therapy Product Procedures Manual			
Johnson	Document No.:	TV-eFRM-13010	Version:	3.0

## **5.2** Review of Packing Materials

This section describes the packing materials required for packing apheresis material.

Review	of Packing Materials	
Step	Task	Responsibility
5.2.1	Applicable for USA only (For Canada, please see next table):	Clinical Site
	Receipt of CREDO CUBE Shipper.	
	Check that the CREDO CUBE shipment contains the following:	
	Outer corrugated box	
	<ul> <li>Inside the corrugated box there is the CREDO CUBE shipper (do not remove it from the box)</li> </ul>	
	<ul> <li>Inside the CREDO CUBE there is a brown payload box (do not remove from the CREDO CUBE)</li> </ul>	
	Inside the brown payload box there is:	
	Clinical site kit pouch	
	Cryopreservation kit pouch	
5.2.2	Applicable for USA only (For Canada, please see next table): The clinical site kit pouch contains the materials used for packing of apheresis material. The Clinical Site kit pouch includes:	Clinical Site
	Non activated temperature monitoring device (TempTale Ultra) - keep inside CREDO CUBE until it is time to activate.	
	Polybag	
	Absorbent pad	
	AWB for shipment to the CPC	
5.2.3	Applicable for USA only (For Canada, please see next table):	Clinical Site
	Keep the cryopreservation kit pouch inside the brown payload box. Do not remove as it is intended for future use at the CPC.	
	Notify CSOM via email <a href="mailto:Central.Scheduling@ITS.JNJ.com">Central.Scheduling@ITS.JNJ.com</a> and copy the SM if any contents are missing or temperature monitoring device activated prior to receipt at the site.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISON&OOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Review o	FPacking Materials	
Step	Task	Responsibility
5.2.1	Applicable for Canada only:	Clinical Site
	Receipt of CREDO CUBE Shipper	
	Check that the CREDO CUBE shipment contains the following:  CREDO CUBE shipper  Large Polythene Bag containing:  Polybag  Absorbent material	
	Non activated temperature monitoring device (TempTale Ultra)- keep inside CREDO CUBE until it is time to activate.  World Courier may include a Real Time Location Monitoring Device (RTLM) in the credo cube for tracking purposes (data will not be shared). The RTLM device will be positioned outside the box, ensuring there is no physical	
	contact with the apheresis bag. Do NOT remove the RTLM device.  AmerisourceBergen World Courier RTLM - Controlant GPS World Courier Property - Do Not Touch!  Placement of the RTLM device inside credo cube  Label on the plastic pouch containing RTLM device  This information is included here only for reference.	
1	Notify CSOM via email <u>Central.Scheduling@ITS.JNJ.com</u> and copy the SM if any contents are missing or the temperature monitoring device was activated prior to receipt at the site.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

# 5.3 Packing of Apheresis Material into the CREDO CUBE Shipper for USA only

This section provides step-by-step instructions for packing the apheresis material into the CREDO CUBE shipper.

Applicable for USA only (instructions for Canada, please see pages XX-XX)

Packing	of apheresis material into the CREDO CUBE Shipper	
Step	Task	Responsibility
5.3.1	Prior to starting packing:  Verify that the subject number on the AWB matches the subject number listed on:  Copy of the IRT notification which includes DIN /Apheresis ID. (If not available, contact site coordinator and request copy prior to continue to the next steps)  Sponsor apheresis label Shipper label	Clinical Site
5.3.2	Open outer corrugate box containing the empty CREDO CUBE shipper.  Outer Corrugated Box  Outer Corrugated Box	Clinical Site
5.3.3	Open the top panel and remove the VIP panel.  VIP Panel  VIP Panel	Clinical Site
5.3.4	Open the White TICTM Panel and remove it.  White TIC Panel  White TIC Panel	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OUTHSUITAOUTHSUIT	Document No.:	TV-eFRM-13010	Version:	3.0	,

#### **5.3.5** Brown payload box

Clinical Site

Open and remove the clinical site kit pouch and display its components on a flat surface. **NOTE: Leave TempTale inside the brown payload box until is time to activate**.



**IMPORTANT:** Leave the cryopreservation kit pouch inside the brown payload box within the CREDO CUBE. This is for the CPC.



#### **5.3.6** Once the subject information on the site apheresis label is verified:

Clinical Site

- Place apheresis material into the polybag with the absorbent pad.
- Remove the adhesive backing and seal the polybag with the apheresis material inside.





Gently place the polybag containing the apheresis material inside the brown payload box within the CREDO CUBE.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

#### Applicable for USA only

Pac	king of apheresis material into the CREDO CUBE Shipper	
Step	Task	Responsibility
5.3.7	<ul> <li>Remove the TempTale from inside the brown payload box.</li> <li>Press on the Green Start button until the "SUN" icon appears.</li> </ul>	Clinical Site
	IMPORTANT: If any of these icons appears on the screen, notify CSOM via email Central.Scheduling@ITS.JNJ.com_and copy the SM immediately:  Alarm status alarms alarms status alarms stat	

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

#### Applicable for USA only

Packing	of apheresis material into the CREDO CUBE Shipper	
Step	Task	Responsibility
5.3.8	Close and secure the top White TIC™ panel of the shipper	Clinical Site
5.3.9	Place the VIP Panel on the top and secure the outer corrugated box with tape.  VIP Panel  VIP	Clinical Site
5.3.10	<ul> <li>Once the shipper is secured:</li> <li>Place the shipper label and AWB into the packing envelope.</li> <li>Ensure the existing AWB has been removed and the new shipping AWB replaces it.</li> <li>The shipper is now ready for pick-up by the courier.</li> </ul>	Clinical Site
1	IMPORTANT! In case of issues encountered during the packing process, notify CSOM via email Central.Scheduling@ITS.JNJ.com and copy the SM.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual			
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0

# 5.3 Packing of Apheresis Material into the CREDO CUBE Shipper for Canada only

#### Applicable for Canada only (instructions for USA, please see pages XX-XX)

This section provides step-by-step instructions for packing the apheresis material into the CREDO CUBE shipper.

Pack	king of apheresis material into the CREDO CUBE Shipper	
Step	Task	Responsibility
5.3.1	Prior to start packing:  Remove the AWB from the outer pouch and verify that the Subject Number on the AWB matches the Subject Number listed on:  Sponsor apheresis label Shipper label  World Courier*  AmerisourceBergen  ACCOUNT #:  354512  BILLING REFERENCE: Subject #  FROM (SHIPPER)	Clinical Site
5.3.2	Open outer corrugate of the empty CREDO CUBE shipper.	Clinical Site
5.3.3	Open the top panel and remove the VIP panel.  VIP Panel	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.	0

Pack	king of apheresis material into the CREDO CUBE Shipper	
Step	Task	Responsibility
5.3.4	Remove the White TICTM Panel.  White Tic	Clinical Site
5.3.5	Check contents inside the CREDO CUBE:  • Locate the Large Polythene, which contains the following:  • Polybag  • Absorbent pad  • Non-activated temperature monitoring device (TempTale Ultra)- leave inside shipper until ready to activate	Clinical Site
5.3.6	Once the subject information is verified:  Place the apheresis material bag into the polybag with the absorbent pad.  Remove the adhesive backing and seal the polybag with the apheresis material inside.  Gently place the polybag into the CREDO CUBE	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Pack	king of apheresis material into the CREDO CUBE Shipper	
Step	Task	Responsibility
5.3.7	Activate the TempTale:  Remove the logger from inside the CREDO CUBE  Press on the Green Start button until the "SUN" icon appears.	Clinical Site
	IMPORTANT: If any of these icons appears on the screen, immediately notify CSOM via email Central.Scheduling@ITS.JNJ.com and copy SM:  Alarm status  Alarm triggered A HiGH/* LOW  Stopped recording	
5.3.8	Once activated:  • Place the TempTale into the CREDO CUBE next to the packed Polybag.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Pack	ing of apheresis material into the CREDO CUBE Shipper	
Step	Task	Responsibility
5.3.9	Close & secure the top White TIC™ panel of the shipper.	Clinical Site
	TIC	
	Place the VIP Panel on the top.	
	VIP	
5.3.10	Secure the outer corrugated box with tape.	Clinical Site
5.3.11	Once the shipper is secured:	Clinical Site
	Place the completed sponsor shipper label and the existing AWB into the packing envelope.      This side UP	
	The shipper is now ready for pick-up by the courier.	

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## 5.4 Courier Pick Up of the Packed CREDO CUBE Shipper

Cour	Courier Pick Up of Packed CREDO CUBE Shipper				
Step	Task	Responsibility			
5.4.1	The sponsor will coordinate with the courier to return that afternoon to pick up the apheresis material at <b>agreed local time</b> for delivery to the CPC.	Sponsor			
<u> </u>	IMPORTANT Notify CSOM via email Central.Scheduling@ITS.JNJ.com if the packed Credo Cube will not be ready for pick-up by the courier by agreed local time.  Should the pickup time be delayed, alternate plans may need to be implemented based on flight or ground transportation constraints.	Clinical Site			

രാ	COC/COI ACTIONS:	Responsibility
	Complete the Site Shipment Form for Chain of Custody/Chain of Identity Form (see NA_SHIP_APH)	Clinical Site
£	Upload a signed copy of this form to the MBOX on the same day.	Clinical Site

# **MODULE 5 COMPLETED**

Johnson&Johnson	Cell Therapy Product Procedures Manual			
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0



# **Module 6:**

# Receipt and Storage of the Investigational Product

Version: 5.0

Date: 12-APR-2024

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

# **Module 6: Table of Contents**

- 6.1 Communication Plan with Site, Courier & Sponsor
- **6.2** Review of Packing Materials
- 6.3 Receipt of the LN<sub>2</sub> shipper containing Investigational Product
- 6.4 Unpacking and Storage of Investigational Product
- 6.5 Prepare of Empty LN<sub>2</sub> Shipper for Shipment
- 6.6 Storage and Monitoring of IP
- **6.7 Problems and Special Situations**

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

# **Module 6: Revision History**

This is a controlled document.

VERSION DATE DD-MON-YYYY	SECTION(S) CHANGED	DESCRIPTION OF CHANGE(S)
01-Mar-2021	Initial Document	
05-Jul-2021	6.3 6.4 6.7	Updated information for temperature excursions  Updated instructions on placement of DV10 smart cap  Section related to PQC's has been updated to include damage to secondary container 'Cassette'  Cryogenic Containment Pouch added as scheduled for August 2021 roll out
10-Mar-2022	6.1.1	Step updated to include CQUENCE clinical trials portal process  Added Certificate of Compliance & CAR-T Final Release Form to be edited per region
	6.3.4 6.6 6.7	Edited shipper documents provided per region  Updated requirements for onsite transport between two locations  Updated statement for PQC to include bag and or cassette
28-Mar-2022	Module 6	Formatting and administrative changes
06 Mar 2023	Module 6 6.1.4	Removed references to Vineti  Deleted reference to courier phone call
	6.2.3 6.3.6 6.4.5	Added QR code to list to check prior opening box  Added instruction for how and when to use QR code. Included pictures of QR code  Added instructions for handling cassette and IP bag on receipt
12-APR-2024	6.1.2	Minor wording update to the type of shipments expected  Further specified the courier companies per region
	6.1.6 6.2.2, 6.3.4, 6.4.1, 6.4.6 6.2, 6.3	Added courier responsibility  Updated wording to reflect that either certificate or compliance or CAR-T Final Release Form will be included with IP shipment documentation.  Removed references to obsolete videos
	,	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISON&OOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

6.3.5	Updated pictures
6.4.2, 6.4.4, 6.4.7	Added instructions to unpack multiple cassettes
6.4.5	Clarified the requirement to inspect both cassettes and IP bags
6.4	Updated wording for MBOX system & COC/COI Actions table
6.6	Consolidated IP warning and storage requirements Clarified documentation requirements for cryopreserved IP transport

Johnson&Johnson	Cell Therapy Product Procedures Manual			
	Document No.:	TV-eFRM-13010	Version:	3.0

## 6.1 Communication Plan with Site, Courier & Sponsor

The IP shipment procedure involves two steps:

- 1. Shipment of IP from manufacturing facility to the site
- 2. Shipment of empty LN<sub>2</sub> shipper back to sponsor (for recharge/reuse).

If a situation falls outside of the shipments listed below, or the shipments related to the receipt of IP, notify CSOM via <a href="mailto:Central.Scheduling@ITS.JNJ.com">Central.Scheduling@ITS.JNJ.com</a> and copy the SM for further instructions.

	munication plan with Site, Courier & Sponsor	Doonopaibilit.
Step	1.55.	Responsibility
6.1.1	Once manufacturing has started, the site will be able to book the IP on-site date within the CQUENCE Clinical Trials portal.	Clinical Site
	If the IP on-site date needs to be rescheduled, the site should reach out to <a href="mailto:central.Scheduling@its.jnj.com">Central.Scheduling@its.jnj.com</a> to alert the CSOM to schedule a new date.	
	The sponsor will review the initially scheduled IP on-site date (as well as any potential rescheduled dates) and approve the shipment date. The currently approved date of IP on site will always be visible on the specific patient journey page in the CQUENCE Clinical Trials portal.	Sponsor
6.1.2	In alignment with the approved IP on-site date, the sponsor will initiate order delivery once the IP has been released from manufacturing quality.	Sponsor
6.1.3	The courier will issue an automated pre-alert/order confirmation to the site.	Courier
	The notification will reference the subject number and the AWB number to track and trace the shipment.	
	NOTE: A print-out of the same AWB will be provided in the consignee kit pouch within the shipper.	
6.1.4	The courier will send one notification to the clinical site contact(s) prior to delivery of the shipper. The notification will be:	Sponsor/ Courier
	• The day of delivery, within 1 hour prior to delivery. This is a geofence notification and will trigger when the shipment is within a 5-mile radius of the clinical site.	
	NOTE: The site or the sponsor local team does not have access to the EVO-IS system temperature data.	
	Any delays in shipment date will be communicated by the courier via e-mail to the designated site contact.	
6.1.5	The shipper will arrive at the site at the agreed local time for the receipt of the IP.	Courier
6.1.6	The sponsor will coordinate with the courier to pick up the empty shipper at the agreed local time.	Sponsor/ Courier
	IMPORTANT! Notify the CSOM via <a href="mailto:Central.Scheduling@ITS.JNJ.com">Central.Scheduling@ITS.JNJ.com</a> and copy the SM immediately if the empty shipper will not be ready for pick-up by the courier by agreed local time. Should the pick-up time be delayed, alternate plans may need to be implemented based on flight or ground transportation constraints.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISON&OOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## **6.2** Review of Packing Materials

This section describes the materials required for unpacking IP.

Review	of packing materials					
Step	Task	Responsibility				
6.2.1	Upon receipt of the IP, check to ensure all necessary contents and packaging materials are present.	Clinical Site				
	As a reminder, the following tools should be utilized in preparation for site unpacking of $LN_2$ shipper:					
	• Cryogloves					
	Safety glasses					
	Wire cutters (these are NOT included in the shipment).					
	NOTE: Adhere to any additional site requirements for PPE when handling cryopreserved products and equipment.					
	Do not discard any contents or packaging materials until you have read these instructions.					
6.2.2	Upon the receipt of the shipper, you will find the following components inside the outer shipper case:	Clinical Site				
	• LN₂ shipper (Savsu DV-10)					
	• Consignee Kit pouch (inside the pouch within the shipper case)					
	Certificate of Compliance or CAR-T Final Release Form					
	<ul> <li>Cassette rack with IP: located inside of LN2 shipper, secured with red tamper evident seal and wire (can be verified once LN₂ shipper is opened).</li> </ul>					
	The consignee kit pouch includes:					
	Materials used by the site when shipping the empty LN₂ shipper:					
	<ul> <li>1 zip tie (for use on the outer shipper case). A back-up zip tie will be included.</li> </ul>					
	AWB for return shipment of empty shipper					

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

	y of packing materials	
Step	Task	Responsibility
6.2.3	NOTIFY CSOM via Central.Scheduling@ITS.JNJ.com and cc the SM IF:	Clinical Site
	The shipping container case is not secured.	
STOP	The zip tie is missing from the outer case lid.	
	The subject number listed on the AWB does not match the intended subject.	
	<ul> <li>The EVO-IS ID (last 4 digits) listed on the AWB does not match the LN<sub>2</sub> shipper.</li> </ul>	
	The tamper evident seal number (SEAL#) listed on the AWB does not match the tamper seal on the shipper lid.	
	Any contents are missing from the consignee kit pouch listed above.	
	There is a flashing alarm indicating the temperature is out of range on the display.	
	The temperature light indicator is not functioning.	
	<ul> <li>The temperature is unable to be confirmed using the QR code on the LN<sub>2</sub> shipper lid when the temperature light indicator is not functioning.</li> </ul>	
	Shipping Container and Components	
	DO NOT X-RAY	

Johnson&Johnson	Cell Therapy Product Procedures Manual			
JOHNSON & JOHNSON	Document No.:	TV-eFRM-13010	Version:	3.0

## 6.3 Receipt of the LN<sub>2</sub> Shipper Containing Investigational Product

This section outlines step-by-step instructions for receipt of the packed LN<sub>2</sub> shipper containing IP.

Rec	eipt of the LN <sub>2</sub> shipper containing IP	
Step	Task	Responsibility
6.3.1		Clinical Site
	DO NOT YEAR	
6.3.2	The outer corrugated case is secured by buckle straps.	Clinical Site
	Unclip the buckle straps. Open the outer corrugated case lid.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
	Document No.:	TV-eFRM-13010	Version:	:	3.0

Rec	eipt of the LN₂ shipper containing IP	
Step	Task	Responsibility
6.3.3	The outer case shipper lid is secured by a single zip tie through the zipper pulls.	Clinical Site
	Cut and discard the zip tie then unzip the outer case lid.	
	NOTE: The site will need to use wire cutters (these are NOT included in the shipment)	
6.3.4	Lift the outer shipper case lid.  • Remove and verify that the pouch within the outer case contains the consignee kit pouch. The pouch contains:	Clinical Site
	Shipper label(s)	
	<ul> <li>One (1) zip-tie to secure the outer shipper lid prior to return.</li> </ul>	
	AWB use to return the empty LN <sub>2</sub> shipper.  Contiferate of Consultance and CAR T. Final Release Forms.	
	<ul> <li>Certificate of Compliance or CAR-T Final Release Form</li> </ul>	
	Take out materials from the consignee kit pouch.	
	Pouch within outer case Consignee kit pouch	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Step	Task	Responsibility
6.3.5	Verify that the EVO-IS ID number (last 4 digits) on the AWB matches the EVO-IS ID number on the $\text{LN}_2$ shipper lid. Examples below:	Clinical Site
	QuickSTAT AWB	
	Stat U.S. (718) 995-31 U.K. +44 France +33	
	Bill Shipper Acct No. 13885  PICK-UP Agent Date Time	
	World Courier AWB	
	RECT BY WC (NAME): PAU TIME: PAU DATE:  TO (CONSIGNEE)	
	Name Telephone Address	
	NFORMATION  KUP (Last 4) EVO#2181 Seal #0660603	
	EVO-IS ID number location	
	99000512002181	
	Contact us: 1.505.466.1962 info@savsu.com  263D Alamo Ame. SE Suite 101 Albuquenque, NM 67106 USA	

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOIIISOII & OOIIIISOII	Document No.:	TV-eFRM-13010	Version:	3.0

#### **6.3.6** Confirm if there is any temperature excursion:

Clinical Site

- To determine if the temperature is within range, press the light indicator, release & wait for 5 seconds on the DV-10 lid. The indicator will emit a light. A steady light indicates that the temperature is within range. You can proceed to the next steps.
- A flashing light indicates a temperature excursion has occurred. You can proceed to unpack the IP and follow the instructions outlined in Section 6.7 Problems and Special Situations for temperature excursion reporting guidance.
- If no light is present, scan QR code on DV-10 lid with a smart device. Scanning the QR code will direct the user to a web page that displays the last reported payload temperature with the last recorded temperature reading. This QR code should only be used as a BACK UP solution in case the light indicator fails.

NOTE: The QR code label and the QR code displayed on the web page are correlated with the EVO-IS ID. Verify that the EVO-IS ID on the web page display exactly matches the QR code label ID and EVO-IS ID on the DV-10 lid. Confirm on the QR code temperature snapshot display that the time stamp is current.

- If any of the following occurs, remove the IP from the LN<sub>2</sub> shipper, place in the proper storage condition, and notify CSOM via Central. Scheduling@ITS. JNJ. com and copy the SM:
  - A flashing light indicating a temperature excursion has occurred.
  - Temperature light indicator is not functioning (does not turn on)
  - There is any ID mismatch, concerns regarding the QR code, and/or an out-ofrange temperature

#### **Press Indicator**








Example of QR code and web page display:







Johnson&Johnson	Cell Therapy Product Procedures Manual			
ooniison aooniison	Document No.:	TV-eFRM-13010	Version:	3.0

Receipt of the LN <sub>2</sub> shipper containing IP					
Step	Task	Responsibility			
6.3.7	Verify the tamper evident seal number (SEAL#) listed on the AWB matches the tamper evident seal number located on the LN <sub>2</sub> shipper lid.	Clinical Site			

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 6.4 Unpacking and Storage of Investigational Product

In the following section there are step-by-step instructions for unpacking the IP from the shipper. It is recommended that two personnel work together during this process.

**REMINDER:** Ensure all necessary PPE is used before the next steps. Also, ensure that the COC/COI form is available for reference and completion.

IMPORTANT: IP must be placed into storage immediately following removal from the LN₂ and verification of COC/ COI.

Unpa	cking and Storage of IP	
Step	Task	Responsibility
6.4.1	<ul> <li>Make sure the following documents are available to conduct COC/COI checks:         <ul> <li>Certificate of Compliance or CAR-T Final Release Form</li> <li>Confirmation of the IP lot number from IRT</li> </ul> </li> <li>Cut and discard the zip tie and tamper seal on the shipper lid so it can be opened when necessary.</li> </ul>	Clinical Site
	NOTE: The site will need to use wire cutters (these are NOT included in the shipment).	
STOP	NOTE: Proper placement of the DV10 Smart Cap when not seated in the dewar body is PROBE SIDE UP on a flat surface. Serious damage to the probe may occur if placed otherwise.	Clinical Site
STOP	IMPORTANT: Next steps below need to be performed as quickly as possible. It is critical to pack the cassette(s) into the LN₂ freezer quickly to avoid thawing of the IP.	Clinical Site
6.4.2	Remove the shipper lid and lift the cassette rack.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3	.0

Step	cking and Storage of IP  Task	Responsibility
	<ul> <li>As soon the rack containing IP cassette(s) is pulled out of the shipper; start the timer to monitor IP exposure to room temperature for each cassette.</li> <li>Ensure the exposure time does not exceed 3 mins. The timer will be stopped when each cassette is placed in the vapor phase of LN<sub>2</sub>.</li> </ul>	
	Close the shipper lid once the rack is removed.	
6.4.3	Using a wire cutter:	Clinical Site
	Cut and discard the tamper evident seal wire (labeled RACK) on the cassette rack.      The control of the cassette rack.	
	Remove dunnage located on top of the envelope within the cassette rack.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Step	Task	Responsibility
6.4.4	Remove the cryogenic containment envelope pouch containing one IP cassette from the rack slots.	Clinical Site
	NOTE: In case of multiple IP cassettes packed in the same shipper/rack: Immediately reinsert the rack with remaining cassettes back into the LN2 shipper and close the lid of the LN2 shipper.  The lid of LN2 shipper uses a smart cap with built in thermocouple. When lid is removed	
	the thermocouple warms up to ambient temperature. To avoid temperature excursions, secure lid back on shipper when multiple bags are being unpacked.	
	Cut open the pouch and remove the cassette.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Task		Responsibility
	to placing cassettes in LN₂ storage, each cassette and IP bag needs to be ked. Check the integrity & label accuracy of each cassette and IP bag.	Clinical site
•	When the cassette containing the IP bag is removed from vapor phase LN <sub>2</sub> , and is in the frozen state, the IP bag is brittle.	
•	It is very important to handle the cassette and IP bag with care to avoid damage.	
•	There are three (3) ports on the bag as shown below, which must be intact on receipt.	
	center line	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Unpa	cking and Storage of IP	
Step	Task	Responsibility
6.4.6	Prior to placing the cassette into the site LN <sub>2</sub> storage, verify the following:	Clinical Site
	Subject # on each bag and cassette label matches the information on the:	
	• AWB	
	• IRT	
	Shipper label	
	Certificate of Compliance or CAR-T Final Release Form	
	The unique identifier (DIN or Apheresis ID or SEC) on each bag and cassette label matches the information on the:	
	• IRT	
	Shipper label	
	Certificate of Compliance or CAR-T Final Release Form	
	IP Lot # on each bag and cassette label matches the information on the:	
	• IRT	
	Shipper Label	
	Certificate of Compliance or CAR-T Final Release Form	
	Note: IP cassette(s) should not be exposed to ambient temperature greater than 3 minutes.	
	IMPORTANT: If 3 mins is exceeded, notify CSOM via Central.Scheduling@ITS.JNJ.com and copy the SM.	
	Please refer to Module 6, section 6.7 for instructions on reporting Temperature Out-of-Range (TOR) Events & Quarantining.	
	Complete the required COI/ COC form.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0	0

Step	Task	Responsibility
6.4.7	<b>₹</b>	Clinical Site
	Repeat steps 6.4.2, 6.4.4, 6.4.5, 6.4.6 with each subsequent IP cassette.	
	Place the empty cassette rack into the shipper.	
	Lower the shipper handle to allow for the closing of the shipper lid.	
	Close the LN <sub>2</sub> shipper lid.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

രാ	COC/COI ACTIONS:	Responsibility
	Complete the IP Shipment Receipt Checklist for Site (see NA_REC)	Clinical Site
<b>£</b>	Upload a signed copy of this form to MBOX on the same day.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 6.5 Prepare of Empty LN<sub>2</sub> Shipper for Shipment

After completion of the IP Shipment Receipt Checklist for Site, the site will prepare the empty shipper for shipment.

Prei	Prepare Empty LN <sub>2</sub> Shipper for Shipment						
Step							
6.5.1	•	Obtain the zip tie provided in the consignee kit pouch.	Clinical Site				
	•	Zip the outer case lid closed and secure by passing the single zip tie through the zipper pulls.					
	•	Fasten the lid of the outer corrugated case by fastening the buckle straps.					

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OUTHSUITAOUTHSUIT	Document No.:	TV-eFRM-13010	Version:	3.0	

6.5.2	<ul> <li>Place the AWB into the clear packing envelope for courier pick-up.</li> <li>Discard all leftover materials and packaging per site disposal procedures.</li> </ul>	Clinical Site
	<b>REMINDER:</b> The sponsor will coordinate with the courier to pick up the empty LN <sub>2</sub> shipper from the site at the agreed local time.  Notify CSOM via <a href="mailto:Central.Scheduling@ITS.JNJ.com">Central.Scheduling@ITS.JNJ.com</a> and copy the SM immediately if there are any constraints for getting this shipment ready for agreed local time.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 6.6 Storage and Monitoring of IP

IP must be stored according to the conditions on the label, in a secure location with limited access.

## Warnings & Storage Requirements:

IP must be stored according to the conditions on the label, in a secure location with limited access.

JNJ-68284528 (ciltacabtagene autoleucel) must be kept frozen at ≤-120°C vapor phase of liquid nitrogen. For frozen IP, maintenance records for the liquid nitrogen storage system must be available for sponsor review.

During on-site storage and during any internal transportation between sites, **IP must not be separated from the cassette**. The packaging is designed to protect the drug from breakage and damage and parts should not be separated.

When the cassette containing the IP bag is removed from the vapor phase LN2 temperature and is in the frozen state, the IP bag can be brittle. It is very important to handle the cassette and IP bag with care to avoid damage.

IP cassette(s) should not be exposed to ambient temperature greater than 3 minutes.

All documentation/data of the storage temperature must be retained in accordance with the records retention policy outlined in the Protocol and Clinical Trial Agreement, and applicable legal and regulatory requirements

## **Storage**

#### Storage Temperature Monitoring of IP

The use of a temperature monitoring device is required for the storage of all IP. Temperature conditions during onsite storage must be continuously monitored and recorded (e.g., temperature logs or data, charts or graphs from temperature monitoring equipment or devices). If not continuous (e.g., constant), the data recording interval of the temperature monitoring device should be less than or equal to 4 hours.

All temperature data and documentation must be retained in accordance with the records retention policy outlined in the Protocol and Clinical Trial Agreement, and applicable legal and regulatory requirements.

#### **Transport Temperature Monitoring of IP**

In addition to complying with all warnings and requirements outlined above during any transport of Cryopreserved IP; the following must be documented:

- Time of removal of IP from storage
- Temperature during transport of IP from the storage location to the administration site; or at the minimum temperature upon removal of cassette from transport equipment.

#### **Frequency of Temperature Monitoring Verification**

The output of the temperature monitoring device must be verified, and this verification recorded on a temperature log/temperature alarm log, at a minimum, daily, during site working days.

If a temperature out- of-range (TOR) occurs during the weekend or holiday, report it on the morning of the first working day following the weekend or holiday.

A blank Temperature Log and a Temperature Alarm Log can be found in the Blank Forms section of the Site IP Binder; the SM will advise you on which form(s) apply to your site. Temperature Logs must identify or link to (e.g., through the serial number or unique identifier) the temperature monitoring device and, if applicable, the LN<sub>2</sub> storage system.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison	Document No.:	TV-eFRM-13010	Version:	3.0	

#### Storage temperature monitoring with a site's own monitoring equipment

In order to ensure that the temperature monitoring equipment continues to meet expectations throughout the study, it must be calibrated in accordance with the manufacturer's recommendations. If the frequency of calibration is not specified, the device must be calibrated at least annually. Calibration and maintenance documentation for the LN<sub>2</sub> storage system must be filed and made available for review.

When the site's temperature monitoring device is equipped with audible and visible alarms to attract immediate attention in the event of a TOR, the proper functioning of these alarms must also be periodically tested and documented.

## Storage and Monitoring of IP

#### Periodic checking of the temperature measurements

The temperature monitoring device must be checked to verify that temperatures have stayed within the acceptable range. Depending on the type of temperature monitoring device that the site uses, there are different options:

### ⇒ Temperature monitoring device with audible/visible alarms:

The audible and/or visible alarm will alert the cell processing laboratory staff of a temperature out-of-range situation and the procedure for reporting a TOR must be followed.

Even when the system has not alarmed, the temperature records generated by the system should be periodically reviewed to verify that all temperature measurements were within range. The SM will check the temperature records at periodic monitoring visits.

#### ⇒ Temperature monitoring equipment without audible/visible alarms:

When temperature monitoring equipment is not equipped with an audible or visible alarm, then the temperature monitoring equipment must be checked according to the frequencies in the previous section to verify that no TOR has occurred. This check must be documented on a Temperature Alarm Log or Temperature Log.

#### Replacing site-owned temperature management equipment & Relocation of IP

When the equipment (LN<sub>2</sub> storage system) used to store or the equipment used to monitor the storage temperature (e.g., temperature probe) of IP is replaced, the new equipment must undergo an assessment to determine whether it is acceptable for use in the study. <u>Before the equipment is replaced</u>, contact the SM for an assessment and acceptance of the new equipment.

The same requirement applies if the IP will be permanently moved to another liquid nitrogen storage system that has not been assessed and determined to be acceptable for storage of the IP. Assessment does not apply to emergency situations (power outage or equipment failure) necessitating the temporary movement of IP.

#### Preparation, Dispensing and Administration of IP

See the Protocol, Investigators Brochure, and Investigational Product Preparation Instructions (IPPI) for sponsor instructions on preparing, dispensing, and administering the IP. The IPPI is located in the site IP binder.

Follow local guidelines and standard procedures for preparation of IP in alignment with sponsor instructions.

It is best practice for two qualified staff members to be involved whenever the IP is prepared; one to prepare the IP and the other staff member to verify. Guidance on the use of sponsor provided or site provided ancillary supplies in the IPPI.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## 6.7 Problems and Special Situations

This section applies to both LN<sub>2</sub> shipping container and site's LN<sub>2</sub> storage TORs.

## **Problems and Special Situations**

#### **Temperature Out-of-Range (TOR) Events**

Immediately upon discovery of a TOR take the following steps:

- Quarantine the affected IP supplies. It is important not to use supplies that have experienced a temperature excursion. (Refer to Quarantining)
- Remove the product from the cryoshipper and place the product in the LN<sub>2</sub> storage following the instructions provided in the Shipping section above.
- Immediately notify CSOM via <a href="mailto:Central.Scheduling@ITS.JNJ.com">Central.Scheduling@ITS.JNJ.com</a> and copy the site manager of the TOR and discuss the potential impact, providing them with the last 4 digits of the EVO-IS # and the subject #.
  - Immediately following contact with the site manager, complete a TOR report, and send it to the TOR team electronically, copying the site manager/local trial manager. If unable to reach the site manager, move forward with completing the TOR report, send to the TOR team and then resume attempts to escalate to the site manager.
  - > Include the protocol number and site number in the subject line of the email when submitting a TOR.
  - > Be sure to include the last 4 digits of the EVO-IS # and Subject # in the body of the email.
  - Regional fax numbers are listed on the TOR Report Form in the event that the site is not able to e-mail the form.

NOTE: For LN<sub>2</sub> shipper TORs, you do not need to attach the temperature reports to the TOR Report Form, as the TOR team will be pulling these from the EVO-IS shipper readout. For TORs that occur while the IP is in storage on-site, the temperature report MUST be attached with the TOR Report Form.

- The sponsor will complete the relevant section of the TOR Report and indicate whether the IP is acceptable for use or not. In general, you should expect a response within hours, but no longer than 1 working day after sending the report, which may either be a final verdict or a request for more information. If you have not received any response within 24 hours, contact the site manager.
- The sponsor will send the completed TOR Report to the email address from which the TOR Report was sent. The completed TOR Form is the documentation provided by the sponsor to indicate if the IP is acceptable for use or not. File the completed TOR Report from the sponsor with the originally submitted TOR Report in the Site IP Binder.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
ooniison aooniison	Document No.:	TV-eFRM-13010	Version:	3.0	

## **Problems and Special Situations**

#### Quarantining

If it is necessary to quarantine any IP (e.g., damaged, TOR, product quality complaint) the following steps should be followed.

- Notify the site manager/local trial manager immediately.
- Physically separate the IP being quarantined if possible.
- Ensure that the guarantined IP is temporarily identified as "Quarantined" to ensure that it is not used.
- While in quarantine, the IP must be stored and handled according to the study requirements (e.g., LN<sub>2</sub> storage) and procedures. This will prevent further deterioration or damage to the IP while the viability of the IP is being assessed.
- Once quarantined, the IP should ideally remain separated until further notification is received from the sponsor (if IP was quarantined because of a TOR, the completed TOR Form is the notification provided by the sponsor to indicate if the IP is acceptable for use or not).
- If the IP has been quarantined because of a product quality complaint, be ready to provide details and a photograph of the drug and/or packaging to the site manager regarding the complaint so that the site manager can further report the issue to the sponsor.
- After the assessment, the sponsor will inform you of the outcome.
  - If the sponsor indicates that the IP is acceptable for use: Remove the temporary "Quarantined" identification and return it to usable inventory.
  - o If IP was quarantined because of a TOR, the completed TOR Form is the notification provided by the sponsor to indicate if the IP is acceptable for use or not.
  - o If the sponsor indicates that the IP is not acceptable: Identify the IP as 'for return to sponsor'; return it to the LN<sub>2</sub> storage system and await instructions on return to sponsor.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

## **Problems and Special Situations**

#### **Damaged IP**

If the IP is damaged while stored at the site, follow the instructions for Quarantining. Notify the site manager and await instructions on the final disposition of the IP.

#### **Lost IP**

Loss of IP is considered a critical situation by regulatory authorities. If IP is lost while stored at the site, immediately upon discovery of the shortage:

- Contact the site manager.
- Conduct an investigation.
- Submit a written report, signed by the Investigator, to the site manager.

#### **Product Quality Complaints (PQC)**

Do not dispense the IP to a subject if there is a concern about the quality of the product.

#### PQC can include:

- Dramatically unexpected appearance or condition of the IP (e.g., apparent visible particles, dramatically unexpected coloration)
- IP primary container with leak(s)
- Damage to secondary container (cassette)
- Labeling of the IP bag and/or cassette is incorrect (e.g., incorrect protocol number, or incorrect subject information).
- If a potential PQC is identified, the following steps should be followed:
  - Quarantine the affected product (see Quarantine section above). Do not discard it.
  - o Immediately contact the site manager to report the problem and to provide the details. Email a photograph of the IP and/or packaging to the site manager.
- If the PQC is associated with a serious adverse event (SAE), a SAE Report must also be submitted within 24 hours of becoming aware of the event.
  - Assist with the investigation of the problem, when requested.
  - File the Complaint Resolution Letter in the Site IP Binder.

## **MODULE 6 COMPLETED**

Johnson&Johnson	Cell Therapy Product Procedures Manual			
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0



# Module 7:

# Return and On-site Destruction of IP

Version: 5.0

Date: 12-APR-2024

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual		
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## **Module 7: Table of Contents**

## Return

- 7.1 Communication Plan with Site, Courier and Sponsor
- 7.2 Review of Packing Materials
- 7.3 Instructions for Receipt of Empty LN<sub>2</sub> Shipper
- 7.4 Packing of Investigational Product into LN<sub>2</sub> Shipper
- 7.5 <u>Discontinuing or Withdrawing a Subject from Investigational Product</u>

## **Destruction**

7.6 On-Site Destruction of Investigational Product

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual		
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

# **Module 7: Revision History**

This is a controlled document.

	1	
VERSION DATE DD-MON-YYYY	SECTION(S) CHANGED	DESCRIPTION OF CHANGE(S)
01-Mar-2021	Initial Document	
05-Jul-2021	7.1	Updated information for temp excursions and packing materials
	7.2	Updated instructions on placement of DV10 smart cap
	7.4	Added Cryogenic Containment Pouch scheduled for August 2021 roll
	7.6	out
		Changes to section 7.6 Onsite destruction of IP to align with process IRT 'subject information'
10-Mar-2022	7.2.2, 7.3.4, 7.4.8, 7.4.10,	Updated step to include new packing materials
	7.7	Removed section as not applicable to BCMA CAR-T
28-Mar-2022	Module 7	Formatting and administrative changes
	7.6.1	Updated step to clarify CAR-T IP destruction process
06-Mar-2023	7.1.3	Change the geofence to 5 miles
	7.2.2, 7.3.4, 7.4.2, 7.4.5, 7.4.8	Removed 3-piece packing solution
	7.2.3	Added when to use QR code
	7.3.6	Added instructions for how and when to use QR code
	7.5	Moved to module 6 information about Discontinuing or Withdrawing a Subject from Investigational Product
12-APR-2024	7.3.4, 7.3.5, 7.3.7, 7.4.3	Updated pictures
	7.3.6	Added recommendation to verify time stamp on web page when using QR code
	7.4.2	Added details on shipping materials expected
	7.6.2	Clarified documentation requirements prior to on-site destruction
	7.2, 7.3, 7.4	Removed references to obsolete videos
	7.4, 7.6	Updated wording for MBOX system & responsibility

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual			
Oomison	Document No.:	TV-eFRM-13010	Version:	3.0	

## 7.1 Communication Plan with Site, Courier, and Sponsor

There are two types of shipments related to the packaging and shipment of IP back to the Sponsor:

- Shipment of charged empty LN<sub>2</sub> shipper to the site (for loading of IP)
- Shipment of IP from clinical site to the Sponsor

Step	Task	Responsibility
7.1.1	The sponsor will initiate order pick up upon notification by the site that one is needed.	Sponsor
7.1.2	The courier will issue an automated pre-alert/order confirmation to the site.	Courier
	The notification will reference the subject number to track and trace the shipment from clinical site to the sponsor.	
	<ul> <li>The notification will also reference the AWB for the shipment. <u>NOTE</u>: a print-out of the same AWB will be provided in the shipper kit pouch within the shipper.</li> </ul>	
7.1.3	The courier will send one notification to the clinical site contact(s) prior to delivery of the empty charged shipper. The notification will be:	Courier
	<ul> <li>The day of delivery, within 1 hour prior to delivery. This geofence notification will trigger when the shipment is within a 5-mile radius of the clinical site.</li> </ul>	
	NOTE: The site or the sponsor's local team do not have access to the EVO-IS system	
	<ul> <li>Any delays in shipment date will be communicated by the courier via e- mail or phone call to the designated site contact.</li> </ul>	
7.1.4	The charged shipper will arrive at the site at the agreed local time for the pack-out of IP.	Clinical Site
7.1.5	The sponsor will coordinate with the courier to return that afternoon to pick up the IP at the agreed local time for delivery to the manufacturing facility.	Sponsor
<u> </u>	IMPORTANT: Notify CSOM via <a href="mailto:Central.Scheduling@ITS.JNJ.com">Central.Scheduling@ITS.JNJ.com</a> and copy the SM if the packed shipper will not be ready for pick-up by the courier by agreed local time.	Clinical Site

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual		
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## 7.2 Review of Packing Materials

Step	v of Packing Materials  Task	Responsibility
7.2.1	The following tools should be utilized in preparation for site packing and unpacking of the LN <sub>2</sub> shipper:	Clinical Site
	• Cryogloves	
	Safety glasses	
	Wire cutter	
1	NOTE: The site will need to use wire cutters (these are NOT included in the shipment).	
<u> </u>	NOTE: Adhere to any additional site requirements for PPE when handling cryopreserved apheresis products and equipment.	
	Do not discard any contents or packaging materials until you have read these instructions.	
7.2.2	1-Piece Packing Solution: Cryogenic containment envelope pouch and foam dunnage	Clinical Site
	Upon the receipt of shipper, you will find the following components inside the outer shipper case:	
	LN <sub>2</sub> shipper (Savsu DV-10)	
	shipper kit pouch (inside the pouch within the shipper case)	
	consignee kit pouch (inside the pouch within the shipper case)	
	The shipper kit pouch is used when shipping IP back to the sponsor. The shipper kit pouch includes:	
	<ul> <li>One (1) red tamper evident seal (for use on one side of the LN<sub>2</sub> shipper lid, number should match the AWB)</li> </ul>	
	One (1) red tamper evident seal (for use on cassette rack)	
	One (1) zip tie (for use on the outer shipper case lid)	
	<ul> <li>One (1) zip tie (for use on one side of the LN<sub>2</sub> shipper lid)</li> </ul>	
	1-Piece Packing Solution: Cryogenic containment envelope pouch and foam unnage	
	One (1) clear side packing envelope	
	AWB for the IP shipment	
	The consignee kit pouch is used by the sponsor when shipping the empty shipper back to the courier upon receipt of the IP. Information is included here only for reference.	
	One (1) zip tie (for use on the outer shipper case)	
	AWB for return shipment of empty shipper	
	<b>Inside the shipper</b> , there will be an empty cassette rack. This is used to store and secure the cassettes inside the shipper during transport.	

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual		
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual		
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## 7.3 Instructions for Receipt of Empty LN<sub>2</sub> Shipper

The following are step-by-step instructions for receipt of the empty LN<sub>2</sub> shipper in anticipation of packing of the IP.

Inetr	ructions for Receipt of the Empty LN <sub>2</sub> Shipper	
Step	Task	Responsibility
7.3.1	The shipper will arrive inside an outer corrugated case. The outer corrugated case includes wheels and luggage handle for ease of transport.	Clinical Site
	Once the shipper has been transported to the appropriate packaging location, set the shipper upright and lower the luggage handle.	
	DO NOT X-RAY	
7.3.2	The outer corrugated case is secured by buckle straps.	Clinical Site
	Unclip the buckle straps. Open the outer corrugated case lid.	
	The outer case shipper lid is secured by a single zip tie through the zipper pulls.	
	DO NOT X-RAY	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.	0

Inch	victions for Descipt of the Empty I.N. Chipper	
	uctions for Receipt of the Empty LN <sub>2</sub> Shipper	Doonousibility
Step 7.3.3	Cut and discard the zip tie then unzip the outer case lid.	Responsibility Clinical Site
	NOTE: The site will need to use wire cutters (these are NOT included in the shipment).	
7.3.4	Lift the shipper case lid.	Clinical Site
	<ul> <li>When the outer shipper case lid is opened, verify that the pouch within the outer case contains the shipper kit pouch and consignee kit pouch which are labeled.</li> <li>Pouch within outer case:</li> <li>Remove the shipper kit pouch and its materials including the foam dunnage. These materials will be used for packing the IP.</li> </ul>	
	Leave the <u>consignee kit pouch</u> inside the pouch.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

# Instructions for Receipt of the Empty LN<sub>2</sub> Shipper Step Task Responsibility Verify that the EVO-IS ID number (last 4 digits) on the AWB matches the EVO-IS ID Clinical Site 7.3.5 number on the LN<sub>2</sub> shipper lid. **QuickSTAT AWB Example** Stat U.S. (718) 995-31 +44 UK France LAST 4) EVO# 2181 13885 PICK-UP **World Courier AWB Example** REC'D BY WC (NAME): TO (CONSIGNEE) Name Telephone Address **EVO-IS ID number location** 99000512002181 evois.savsu.com Contact us: 1 . 505 . 466 . 1962 info@savsu.com

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOTHISOTIQUOTHISOTI	Document No.:	TV-eFRM-13010	Version:		3.0

	Document No.:   IV-eFRM-13010   Version:	3.0				
Instr	uctions for Receipt of the Empty LN <sub>2</sub> Shipper					
Step	Task	Responsibility				
7.3.6	Confirm if there is any temperature excursion:	Clinical Site				
	To determine if the temperature is within range, press the light indicator, release & wait for 5 seconds on the DV-10 lid. The indicator will emit a light. A steady light indicates that the temperature is within range. You can proceed to the next steps.					
	A flashing light indicates a temperature excursion has occurred.					
	<ul> <li>If no light is present, scan the QR code on DV-10 lid with a smart device. Scanning the QR code will direct the user to a web page that displays the last reported payload temperature with the last recorded temperature reading. This QR code should only be used as a BACK UP solution in case the light indicator fails.</li> <li>NOTE: The QR code label and the QR code displayed on the web page are correlated with the EVO-IS ID. Verify that the EVO-IS ID on the web page display exactly matches the QR code label ID and EVO-IS ID on the DV-10 lid. Verify the time stamp on the web page</li> </ul>					
	display to confirm the temperature reading is recent.					
	Notify CSOM via email Central.Scheduling@ITS.JNJ.com and copy the SM immediately and do not continue if:					
	<ul> <li>A flashing light indicating a temperature excursion has occurred.</li> <li>Temperature light indicator is not functioning (does not turn on).</li> <li>There is any ID mismatch, concerns regarding the QR code, and/or an out-of-range temperature</li> </ul>					
	Press Indicator Light Indicator					
	E-Ight and room of the control of th					
	Example of QR code and web page display:					
	D: 862771041061543					

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Instr	uctions for Receipt of the Empty LN₂ Shipper	
Step	Task	Responsibility
7.3.7	Inside the shipper kit pouch, there are 2 tamper evident seals  • tamper evident seal with "SECURED" and serial number listed  • tamper evident seal with "RACK" listed  Verify the tamper evident seal number (SEAL#) listed on the AWB matches the tamper evident seal from the shipper kit pouch.	Clinical Site
	QuickSTAT  Stat U.S. (718) 995-31 U.K. +44 France +33  Stat U.S. (718) 995-31 U.K. +44 France +33  Stat U.S. (718) 995-31 U.K. +44 France +33  World Science Logistics  World Courier  RECD BY WC (NAME): PAUTIME: PAU DATE:  TO (CONSIGNEE)  Name Telephane Address	
	(Last 4) EVO#2181 Seal #0660603	

Johnson&Johnson	Cell Therapy Product Procedures Manual			
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## 7.4 Packing of Investigational Product into LN<sub>2</sub> Shipper

In the following section there are step-by-step instructions for packing the IP into the LN<sub>2</sub> shipper. **REMINDER**: Ensure all necessary PPE is on before the next steps.



The IP must be placed into the LN₂ shipper <u>immediately</u> following removal from the storage and verification of COC/COI.

	L' CID' ( IN OL'	
Pac	king of IP into LN₂ Shipper	1
Step	Task	Responsibility
7.4.1	after pack-out of the shipper.  1. NA_RTN Site IP Return Shipment Form for Chain of Custody/ Chain of Identity	Clinical Site
	2. Confirmation of the IP lot number from IRT	
7.4.2	Ensure all materials in the shipper kit pouch are removed and staged for the packing of the cassette:  - AWB - Cryogenic containment envelope pouches (x3) - Foam dunnage (x3) - Zip ties (x2) - 2 Tamper evident seals: "RACK" & a numbered seal	Clinical Site



IMPORTANT: The next steps need to be performed as quickly as possible. It is critical to avoid thawing of the IP as the cassette(s) are packed into the shipper. Place all packing materials and shipper as close as possible.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
Oomison	Document No.:	TV-eFRM-13010	Version:	3.0	

Step	ing of IP into LN₂ Shipper │Task	Responsibility
7.4.3	Remove the first cassette (with IP) from LN <sub>2</sub> storage.	Clinical Site
	Prior to packing the cassette, verify that the subject number on the AWB and on the	
	copy of the IRT matches the subject number on the cassette label.	
	As a reminder, the AWB is inside the shipper kit pouch.	
	QuickSTAT AWB Example	
	Stat U.S. (718) 995-3 U.K. +44 France +33	
	13885  PICK-UP  Agent  Date  LAST 4) EVOR 2181  SEAL 9 0600603  Pick-UP  Agent  Date	
	Name Address Subject #	
	World Courier AWB example	
	World Courier* 1313 For New AmerisourceBergen	
	998765 Shipment Reference FROM (SHIPPER)	
	Name Address Subject #	
	Finished Product UN3245 GMO Scal	
7.4.4	Complete Section 1 of the Site IP Return Shipment Form for Chain of Custody/Chain of Identity NA_RTN.	Clinical Site
<u> </u>	This is completed prior to inserting the cassette (with IP) into the cassette rack and LN <sub>2</sub> shipper.	

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

Packing of IP into LN <sub>2</sub> Shipper						
Step	Task	Responsibility				
7.4.5	<ol> <li>1-piece packing (Cryogenic containment envelope pouch):</li> <li>Pre-fold over the scored line shown by the arrow. The pre-fold may fold over the adhesive seal cover.</li> </ol>	Clinical Site				
	<ol> <li>Insert the cassette with the locking hinge toward the top and push completely down past the adhesive seal into the cryogenic containment envelope pouch. Ensure the cassette is not behind the adhesive seal.</li> </ol>					
	3. Peel off adhesive strip cover on top flap.					
	4. Peel off adhesive strip cover on the envelope pouch.					
	<ol> <li>a Seal the cryogenic containment envelope pouch. Ensure to fold flap along pre- folded scored line.</li> </ol>					
	b Start sealing from center of pre-fold and work out to the sides. Seal must not have any wrinkles or gaps.					
	<ol><li>Fold tabs around seal with pressure. Tabs must be sealed as close as possible to the envelope.</li></ol>					
	Sa Sb 6					

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OUTHSUITAOUTHSUIT	Document No.:	TV-eFRM-13010	Version:	3.0	

7.4.7 NOTE: proper placement of the DV10 Smart Cap when not seated in the dewar body is PROBE SIDE UP on a flat surface. Serious damage to the probe may occur if placed otherwise.

Johnson&Johnson	Cell Th	erapy Product Pro	ocedures Manual	
Oomison	Document No.:	TV-eFRM-13010	Version:	3.0

7.4.8 Place sealed cryogenic containment envelope pouch with frozen bag inside the cassette into the cassette rack. Ensure proper orientation so the locking hinge of the cassette is at the top of the rack.

Clinical Site



Place one piece of the foam dunnage on top of the envelope within the cassette rack.



7.4.9 Return the rack into shipper to prevent warming and close the shipper lid.



Clinical Site



Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

7.4.10	Deposit the modeling process for any of the remaining account to be chinned	Clinical Site
	Repeat the packing process for any of the remaining cassettes to be shipped.	
7.4.11	After packing the final cassette:	Clinical Site
	<ul> <li>Secure the cassette rack with the tamper evident seal.</li> <li>Feed the tamper evident seal with "RACK" through the cassette holes and secure.</li> </ul>	
7.4.12	<ul> <li>Remove the shipper lid and place the cassette rack (with IP) into the shipper.</li> <li>Close the shipper lid.</li> </ul>	Clinical Site
7.4.13	Secure the lid	Clinical Site
	Lower the shipper handle	
	SmartCap 10	

Johnson&Johnson	Cell Therapy Product Procedures Manual			
JOHNSON	Document No.:	TV-eFRM-13010	Version:	3.0

# 7.4.14 Clinical Site Feed the tamper evident seal that contains the word "SECURED" and seal number through the metal hook and lid. As a reminder, this seal number needs to match the seal number listed on the AWB. On the other side of the shipper lid, wrap and secure a zip tie through the lid and around the handle. 7.4.15 Once the shipper lid is secured Clinical Site Place the verified shipper label into the pouch. NOTE: Only the consignee kit pouch and the shipper label should remain inside the pouch within the shipper case. 7.4.16 Clinical Site Close the outer shipper case lid and secure by passing the remaining zip tie through the zipper pulls. Secure the outer corrugated case by clipping the buckle straps.

Johnson&Johnson	Cell Th	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0		

		Document	No.:	TV-eFRM-13010	Version:	3.0
7.4.17	•	Remove the existing into the clear packing lf there is an addition clear packing envelopiscard all leftover in	g AWB and place the g envelope. nal shipper label plac	new AWB (from the	e shipper kit pouch) ne new AWB into the I procedures.	Clinical Site

REMINDER: The sponsor will coordinate with the courier to pick up the LN<sub>2</sub> shipper packed with IP from the site at agreed local time.

Notify CSOM via email <u>Central.Scheduling@ITS.JNJ.com</u> and copy SM immediately if there are any constraints for getting this shipment ready by local agreed time.

ලා	COC/COI ACTIONS:	Responsibility
	Complete the Return Chain of Custody/Chain of Identity Form (See NA_RTN)	Clinical Site
£	On completion of the form, upload a signed copy of this form to MBOX on the same day.	Clinical Site

Johnson&Johnson	Cell Therapy Product Procedures Manual				
ooninson & ooninson	Document No.:	TV-eFRM-13010	Version:	3.0	

# 7.5 Discontinuing or Withdrawing a Subject from Investigational Product

#### Discontinuing or withdrawing a subject from study drug

See the Protocol for information on the process for discontinuing or withdrawing a subject from study drug (e.g., JNJ-68284528 (ciltacabtagene autoleucel) is not administered) or for a subject's withdrawal from the study following administration of study drug (e.g., JNJ-68284528 (ciltacabtagene autoleucel) administered).

See Protocol for information on retention of apheresis material and JNJ-68284528 (ciltacabtagene autoleucel) that was manufactured but not administered.

In the event JNJ-68284528 (ciltacabtagene autoleucel) is manufactured, but not administered, follow site standard procedures for return of cellular therapy products to the cellular therapy lab and store at  $\leq$  -120°C. Contact the SM.

Johnson&Johnson	Cell Therapy Product Procedures Manual				
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0	

#### 7.6 On-Site Destruction of Investigational Product

Any IP that is unused, assigned but not dispensed, expired, damaged, and/or that the sponsor deems to be unusable, can be destroyed on-site **AFTER** sponsor approval for destruction is obtained. Prior to the first destruction, site processes and SOPs will be reviewed by the sponsor.

On-	Site Destruction of IP	
Step	Task	Responsibility
7.6.1	<ul> <li>Prior to the <u>first IP destruction</u> at the site, the site must obtain approval from the sponsor.</li> <li>Contact the SM and request approval for onsite CAR-T Investigational Product Destruction.</li> <li>If approval is obtained, proceed to step 7.6.2.</li> <li>If approval is denied proceed to section 7.1 for instructions on the return of IP.</li> </ul>	Sponsor/ Clinical Site
7.6.2	Ensure that the following documents are available for reference and completion before starting the destruction procedure.  • Signed Investigational Product Destruction Questionnaire for Cell Therapy Products  • CAR-T IP On-Site Destruction Form  • Copy of the IRT notification containing the study subject number	Clinical Site
7.6.3	Complete Page 1 of Form CAR-T IP On-Site Product Destruction Form. Obtain PI signature for destruction approval.	Clinical Site
7.6.4	Proceed to IP identification and destruction and complete page 2 of Form CAR-T IP On Site Product Destruction Form.  Follow institutional SOPs.  NOTE: Ensure all necessary PPE used before performing the procedure.	Clinical Site

ര	COC/COI ACTIONS:	Responsibility
	Complete the CAR-T IP On-Site Destruction Form.	Clinical Site
£	Upload a signed COC/COI form to sponsor MBOX on the same day.	Clinical Site

### **MODULE 7 COMPLETED**

Johnson&Johnson	Cell Therapy Product Procedures Manual			
Oomison&oomison	Document No.:	TV-eFRM-13010	Version:	3.0



# Module 8: COI/COC Maps & Forms

Version: 5.0

Date: 12-APR-2024

Johnson&Johnson	Cell Th	nerapy Product Procedures Manual		
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## **Module 8: Table of Contents**

- 8.1 Summary of Chain of Custody and Chain of Identity Documents
- 8.2 Chain of Custody/Chain of Identity Forms
- 8.3 Chain of Custody/Chain of Identity Cryo Forms
- 8.4 Chain of Custody/Chain of Identity Maps
- 8.5 Study/Region Specific Attachments

Johnson&Johnson	Cell Th	ell Therapy Product Procedures Manual		
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## **Module 8: Revision History**

This is a controlled document.

VERSION DATE	SECTION(S)	
DD-MON-YYYY	CHANGED	DESCRIPTION OF CHANGE(S)
01-Mar-2021	Initial Document	
05-Jul-2021 8.4		Updated definitions and naming conventions for all regions and minor wording changes throughout document
		Updated COC/COI Map with new countries
		· USA and Vineti map updated to include the following regions North America/Latin America/Australia/Korea/Singapore
		· Additional Vineti maps added
		· New Saudi Arabia onsite cryopreservation map added
10-Mar-2022	8.1	Updated the summary of COC/COI documents
28-Mar-2022	Module 8	Formatting and administrative changes
	8.3	Added correct form CAR-T IP On-Site Destruction Form TV-FRM-57192
06-Mar-2023	8.6	Deleted this section related to Vineti maps
	8.1	Changes in wording to clarify instructions. Deleted mention of Vineti. Changed in wording to apheresis material
	8.2	Deleted description of the COC/COI form keeping form name. Deleted Vineti
	8.3	Deleted Central from the COC/COI forms description
	8.4	Deleted Local from the COC/COI forms description
	Module 8	Deleted maps for Vineti
12-APR-2024	8.1, 8.3	Replaced NA_APH and NA_TRN forms with new NA_APH-TRN form Updated name of NA_SHIP_APH form
	8.1, 8.2	Updated wording for MBOX system
	8.4	Revised to only specify the COC/COI forms used for on-site cryopreservation.
	8.5	Updated COC/COI maps
	8.6	Deleted previous section 8.6 Chain of Custody/Chain of Identity Central/Local Cryo TEMPLATE Section 8.7 became 8.6 as a result, with an updated attachment list

Johnson&Johnson	Cell Th	nerapy Product Procedures Manual		
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

### 8.1 Summary of Chain of Custody and Chain of Identity Documents

Chain of Custody	and Chain of Identity Documents	
Timepoint	Site Action & Critical COC/COI Step	COC/COI Document
Subject Screened (signs consent form)	Site enters subject information into IRT (refer to IRT manual):  • Date of consent	13-alphanumeric subject code is generated IRT notification email
Subject Randomized/ enrolled	Site completes randomization/enrollment transaction per study design for the subject in IRT.	IRT notification email
Apheresis Collection	<ul> <li>Site enters subject information into IRT on the day of apheresis, as soon as unique identifier is assigned:</li> <li>Name</li> <li>DOB</li> <li>Unique identifier for apheresis (SEC-DIS or DIN or Apheresis ID)</li> <li>Weight in kg on day of apheresis (rounded to 1 decimal point)</li> <li>Subject undergoes apheresis:</li> <li>Site completes NA_APH-TRN using the IRT notification and apheresis collection information.</li> </ul>	NA_APH-TRN
Transfer to shipment facility (for Shipment to CPC)	<ul> <li>If applicable: site transfers custody of the MNC, apheresis material to the cell lab or other department (referred to as "shipment facility") for packing and shipment to CPC.</li> <li>Site completes NA_APH-TRN and uploads the completed NA_APH-TRN form to MBOX on the same day.</li> </ul>	NA_APH-TRN
Shipment of cells: Site → CPC	The site packs the apheresis material in CREDO CUBE shipper and sends to CPC:  • Site completes NA_SHIP_APH using the IRT notification and uploads the completed NA_SHIP_APH to the sponsor MBOX on the day of the shipment.  NOTE: MNC, apheresis material must be stored at 2-8 °C within 60 minutes of collection end time.	NA_SHIP_APH
Receipt of IP: Manufacturing facility→site	Site receives cryopreserved IP in LN₂ shipper from manufacturing facility and stores IP on-site in anticipation of dosing:  • Site completes NA_REC using the IRT notification and uploads to sponsor MBOX on the day of the receipt.	NA_REC

Johnson&Johnson	Cell Th	herapy Product Procedures Manual		
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

#### 8.2 Chain of Custody/Chain of Identity Forms

The table below provides an overview of the sponsor COC/COI form number, form description and form name. The COC/COI form naming convention will be used throughout the document to identify the COC/COI forms. COC/COI forms for your region can be found in your IP binder and on the study portal.

Sponsor COC/COI Form Number	Form Description	Form Name
TV-eFRM-10456	Apheresis Chain of Custody/Chain of Identity Form	NA_APH-TRN
TV-eFRM-10455	Site Shipment Form for Chain of Custody/Chain of Identity	NA_SHIP_APH
TV-eFRM-10449	IP Shipment Receipt Checklist for Site	NA_REC
TV-eFRM-10450	CAR-T IP Return Shipment Form	NA_RTN
TV-FRM-57192	CAR-T IP On-Site Destruction Form	N/A

Johnson&Johnson	Cell Th	nerapy Product Procedures Manual		
OOMISONAOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

## 8.3 Chain of Custody/Chain of Identity Cryo Forms


The table below provides an overview of the sponsor COC/COI form number, form description and CTPPM form name, for on-site cryopreservation. The COC/COI form naming convention will be used throughout the document to identify the COC/COI forms. COC/COI forms for your region can be found in your IP binder and on the study portal.


Sponsor COC/COI Form Number	Form Description	Form Name
TV-FRM-62994	Receipt of Apheresis Material (or MNC, Apheresis) and Cryopreservation at Cryopreservation Center	CRYO
TV-FRM-62995	Shipment of Cryopreserved Apheresis Material (or MNC, Apheresis Cryopreserved) at Cryopreservation Center	SHIP_CRYO

Johnson&Johnson	Cell Th	II Therapy Product Procedures Manual		
OOTHISOTICOOTHISOTI	Document No.:	TV-eFRM-13010	Version:	3.0


#### 8.4 Chain of Custody/Chain of Identity Map - NA

#### **CENTRAL/External Cryopreservation: (see below)**





#### On-site Cryopreservation: (see below)



Johnson&Johnson	Cell Th	nerapy Product Procedures Manual		
OOMISONGOOMISON	Document No.:	TV-eFRM-13010	Version:	3.0

#### 8.5 Study/Region Specific Attachments

Modified CTPPM procedures apply as outlined in the following memorandums:

- EMN28/68284528MMY3005 Module 7
- 68284528SMM2001 Memorandum dated 21-APR-2023
- CLARIFICATION for J&J Innovative Medicine Cell Therapy Product Procedures Manual (CTPPM) Section 6.7
   'Problems and Special Situations': Temperature Out of Range (TOR) Events.

<u>NOTE:</u> The above list is non-exhaustive as additional changes may be necessary prior to the next version update. The memorandums for your region/ study can be found in your IP binder and/ or the study portal. Contact your SM for a current complete list of memorandums.

#### **MODULE 8 COMPLETED**